Medicare Advantage 2025 Spotlight: A First Look at Plan Offerings

Authors: Meredith Freed, Jeannie Fuglesten Biniek, Anthony Damico, and Tricia Neuman
Published: Nov 15, 2024

Note: This analysis was updated on November 25th to reflect the October version of the 2025 CMS Landscape file.Over the last decade, Medicare Advantage, the private plan alternative to traditional Medicare, has taken on a prominent role in the Medicare program. In 2024, nearly 33 million Medicare beneficiaries are enrolled in a Medicare Advantage plan, more than half, or 54%, of the eligible Medicare population.

Despite concerns that modifications to the payment formula and higher utilization would impact the number of Medicare Advantage plans offered in 2025, the Medicare Advantage market appears to be relatively stable. While Medicare Advantage insurers have made some adjustments in their offerings, the average Medicare beneficiary has a choice of more than 30 Medicare Advantage prescription drug (MA-PD) plans, and virtually all plans provide multiple extra benefits like vision, hearing and dental benefits, similar to last year.

This brief provides an overview of the Medicare Advantage plans that are available for 2025 and key trends over time. This analysis uses data from the CMS Landscape files. In general, this brief refers to individual Medicare plans available for general enrollment, excludes Special Needs Plans (SNPs), except where noted, and excludes employer plans. (See methods for more details.) A second, companion analysis, describes premiums and benefits that are available for 2025 Medicare Advantage plans and over time.

Medicare Advantage Highlights for 2025

  • The average Medicare beneficiary will have the option of 34 Medicare Advantage prescription drug (MA-PD) plans in 2025, 2 fewer than the 36 options available in 2024. Across all plans for individual enrollment, including those with and without prescription drug coverage, the average beneficiary has 42 options in 2025, compared to 43 options in both 2023 and 2024.
  • The number of plans available to the average beneficiary varies across states. In 27 states and Puerto Rico, the average beneficiary has a choice of fewer plans in 2025 than in 2024, while in 16 states and DC, the average beneficiary has a choice of more plans, and in six states the number of plans available, on average, stayed the same.
  • Nearly one-third of Medicare beneficiaries (32%) live in a county with more than 50 Medicare Advantage plans available in 2025, up from 7 percent in 2020, and similar to 2024 (33%). Less than 0.5 percent live in a county with no plans available.
  • The average Medicare beneficiary can choose among plans offered by 8 firms in 2025, the same as in 2024. Three new insurers entered the Medicare Advantage market in 2025, while eight firms exited the market in 2025.
  • Major insurers are both expanding into new counties and exiting others. For example, Humana is entering 12 new counties and exiting 70 counties, while UnitedHealthcare is entering 42 new counties and exiting 38 counties. Both insurers are offering plans in nearly 90% of all U.S. counties.
  • About 5% of current Medicare Advantage enrollees in individual MA-PDs (or about 1.4 million people) are in a plan that has been terminated for 2025, while up to 7% of enrollees in MA-PDs (or as many as 1.8 million people) may be affected by a consolidation, meaning they are in a plan where some portion of the 2024 enrollment will be automatically assigned to a different plan in 2025.
  • More than half (58%) of Medicare beneficiaries live in a county (1,188) where at least one firm is offering 10 or more plans for individual enrollment.

Plan Offerings in 2025

Number of Plans

Number of Plans Available to Beneficiaries. For 2025, the average Medicare beneficiary will have access to 34 Medicare Advantage prescription drug (MA-PD) plans, just 2 fewer than the 36 in 2024 (Figure 1). Across all plans for individual enrollment, including those with and without prescription drug coverage, the average beneficiary has 42 options in 2025, compared to 43 options in both 2023 and 2024. Since 2018, the number of plans available to the average beneficiary has doubled. These numbers exclude employer- or union-sponsored group plans, Special Needs Plans (SNPs), PACE plans, cost plans, and Medicare-Medicaid plans (MMPs) that are only available to select populations.

The Average Medicare Beneficiary Can Choose From 34 Medicare Advantage Prescription Drug (MA-PD) Plans in 2025, 2 Fewer Than the 36 in 2024

Total Number of Plans. In total, 3,719 Medicare Advantage plans are available nationwide for individual enrollment in 2025 – a 6% decrease from the number of plans (240 fewer plans) offered in 2024 (Appendix Figure 1).

HMOs account for more than half (56%) of all Medicare Advantage plans offered in 2025 but have declined as a share of all Medicare Advantage plans since 2017 (71% of plans), while during this period local PPOs rose as a share of all plans (Appendix Figure 1). During this period, the share of plans that are local PPOs increased from 24% to 43%. The share of plans that are regional PPOs has slowly declined from around 3% of plans offered in 2017 to 1% in 2025.

While many employers and unions also offer Medicare Advantage plans to their retirees, no information about these 2025 plan offerings is made available by CMS to the public during the Medicare open enrollment period. Employer and union plans are administered separately and may have enrollment periods that do not align with the Medicare open enrollment period.

Special Needs Plans (SNPs). In 2025, 1,445 SNPs will be offered nationwide, an 8 percent increase between 2024 and 2025 (Figure 2).

The Number of Special Needs Plans Has More Than Doubled Since 2018

D-SNPs. Nearly two-thirds of SNPs (63%) are designed for people dually eligible for Medicare and Medicaid (D-SNPs). The number of D-SNPs has increased substantially since 2018, increasing from 401 D-SNPs in 2018 to 909 D-SNPs in 2025 (up from 851 D-SNPs in 2024), suggesting insurers continue to be drawn to this high-need population. In 2024, 5.9 million Medicare beneficiaries are enrolled in D-SNPs.

I-SNPs. The number of SNPs for people who require an institutional-level of care (I-SNPs) nearly doubled from 97 plans in 2018 to 189 plans in 2023, before dropping modestly to 173 plans for 2024 and 160 in 2025. In 2024, about 115,000 Medicare beneficiaries are enrolled in I-SNPs.

C-SNPs. The number of SNPs offered for people with chronic conditions (C-SNPs) has nearly tripled since 2018, from 132 plans that year to 376 plans in 2025 (an increase of 67 plans since 2024). Most C-SNPs focus on people with diabetes, heart disease, or lung conditions, as has been the case since the inception of C-SNPs. For 2025, one firm is offering a C-SNP for people with dementia (different than the one firm offering one in 2024). Two firms are offering C-SNPs for people with mental health conditions (compared to no firms in 2024), and one firm is offering a C-SNP for people with HIV/AIDS, the same one as in 2024. Ten firms are offering C-SNPs for people with end-stage renal disease (up two from 2024). In 2024, 675,000 Medicare beneficiaries are enrolled in C-SNPs.

Variation in Medicare Advantage Plans, by State and County. The number of plans available to the average beneficiary varies across states (Figure 3; Appendix Table 1). In 27 states and Puerto Rico, the average beneficiary has a choice of fewer plans in 2025 than in 2024. In 16 states and DC, the average beneficiary has access to more plans in 2025 than in 2024. In the remaining six states, the number of plans available to the average beneficiary stayed the same. This includes Alaska, which had no plans available in 2025, as in 2024. Connecticut is not included in this calculation – see methods for more details.

The Average Beneficiary Has More or Fewer Plans Available to Choose from in 2025 Depending on the State They Live In

Nearly 2.2 million beneficiaries in 26 counties can choose from 75 or more Medicare Advantage plans in 2025 (down slightly from 29 counties in 2024). In the same 26 counties, beneficiaries can choose from 63 to 73 Medicare Advantage plans with Part D coverage. Similar to the last three years, the counties with the most plan options are predominantly in Pennsylvania and Ohio. In Pennsylvania, for example, beneficiaries can choose from 80 or more Medicare Advantage plans in 10 counties, including Dauphin County (Harrisburg). Beneficiaries in Cumberland, Pennsylvania can choose from 87 Medicare Advantage plans – the most offerings of any county in the U.S. In Ohio, beneficiaries can choose from 80 or more Medicare Advantage plans in 4 counties, including Summit County (Akron) and Cuyahoga County (Cleveland). In Michigan, beneficiaries in Oakland County (Detroit metro area) can choose from 75 plans (Figure 4).

Nearly 2.2 Million Medicare Beneficiaries, in 26 Counties, Can Choose From 75 or More Plans in 2025

In 2025, nearly one-third (32%) of Medicare beneficiaries (in 9 percent of counties) can choose from more than 50 Medicare Advantage plans (Figure 5).

Nearly One-Third of Medicare Beneficiaries (32%) (in 9 Percent of Counties) Have More Than 50 Medicare Advantage Plans Available Where They Live in 2025

Nearly one-third of Medicare beneficiaries (32%) have a choice of at least 50 Medicare Advantage plans in 2025, roughly the same as 2024 (33%). In 2025, less than 0.5 percent of beneficiaries live in a county with one to four Medicare Advantage plans available, while less than 0.5 percent of beneficiaries live in a county without any plans available. Similar to 2024, there are no Medicare Advantage plans for individual enrollment being offered in any county in Alaska in 2025, which includes about 99,000 beneficiaries. In 81 counties, about 250,000 Medicare beneficiaries (including those in Alaska) will not have access to a Medicare Advantage plan (an increase from 58 counties and about 196,000 Medicare beneficiaries in 2024). Additionally, no Medicare Advantage plans are available in territories other than Puerto Rico.

Variation in Medicare Advantage Plans by Geographic Status. Medicare beneficiaries living in metropolitan areas – counties with at least 50,000 people – can choose from 45 Medicare Advantage plans in 2025 on average (down from 47 in 2024), including 37 with Part D coverage, substantially more than beneficiaries living in rural or micropolitan areas. Beneficiaries in micropolitan areas (10,000 to 50,000 people) can choose from an average of 31 plans (1 fewer plan than in 2024), including 24 with Part D coverage.

Beneficiaries in rural areas – counties with less than 10,000 people – can choose from an average of 27 plans (the same as in 2024), including 21 with Part D coverage. Since 2020, when 14 plans were available on average to beneficiaries living in rural areas, the availability of plans in rural areas has nearly doubled.

As in recent years, virtually all Medicare beneficiaries (99.6%) have access to a Medicare Advantage plan as an alternative to traditional Medicare, including almost all beneficiaries in metropolitan areas (99.9%), micropolitan (99.0%) and rural (97.8%) areas.

Medicare Advantage Plan Availability by Firm

The average Medicare beneficiary is able to choose from plans offered by 8 firms in 2025, the same as in 2024 (Figure 6). Despite most beneficiaries having access to plans operated by several different firms, enrollment is concentrated in plans operated by UnitedHealthcare and Humana, and together UnitedHealthcare and Humana account for nearly half (47%) of Medicare Advantage enrollment in 2024.

Nearly One-Third (31%) of Beneficiaries Can Choose Among Medicare Advantage Plans Offered by 10 or More Firms in 2025

In 2025, nearly one-third of beneficiaries (31%), in 169 counties, are able to choose from plans offered by 10 or more firms or other sponsors (a decline from 33% in 2024). In contrast, nearly 5 percent of beneficiaries live in a county where one to three firms offer Medicare Advantage plans (501 counties).

Further, in 126 counties, only one firm will offer Medicare Advantage plans in 2025. These are mostly rural counties with relatively few Medicare beneficiaries (less than 1 percent of total). In some of these counties, there were no firms offering Medicare Advantage in 2024, e.g., 5 counties in Idaho (Benewah, Clearwater, Custer, Lemhi, and Lewis). In contrast, Medicare beneficiaries in some counties had access to plans offered by two or three firms in 2024 but only one firm in 2025, such as people living in Coos County, Oregon.

Availability of Plans by Firm and County. UnitedHealthcare and Humana, the two firms with the most Medicare Advantage enrollees in 2024, have large footprints across the country, offering plans in most counties, similar to 2024 (Figure 7).

Humana's Medicare Advantage Plans Will Be Available in 89% of Counties and UnitedHealthcare's Will Be Available in 87% of Counties in 2025

Some major insurers are expanding into new counties, while leaving others (Figure 8).

In 2025, Some Major Insurers Are Expanding into New Counties, While Exiting Others

Humana is offering plans in more counties than any other large Medicare Advantage insurer – 2,848 counties in 2025 – though that represents a decrease of 58 counties from 2024. Humana is exiting 70 counties, while entering 12 new counties. UnitedHealthcare is offering plans in 2,808 counties in 2025, an increase of 4 counties from 2024. UnitedHealthcare entered more counties (42 new counties) than it exited (38 counties).

Blue Cross Blue Shield Affiliates are offering plans in 2,639 counties in 2025, an increase of 35 counties from 2024. Blue Cross Blue Shield Affiliates are exiting 44 counties, but are entering 79 new counties. CVS is offering plans in 2,249 counties, an increase of 22 counties. CVS exited 65 counties, but is entering 87 new counties.

Insurer decisions to exit some counties while entering new ones may suggest that local market factors impact insurer evaluations about their potential to attract enrollees and earn a profit.

Multiple Plan Offerings by Firms in the Same County. Many Medicare Advantage firms are also offering more than one plan option in each county.

More than half (58%) of Medicare beneficiaries live in a county (1,188) where at least one firm is offering 10 or more plans for individual enrollment. For example, in Cumberland County, Pennsylvania (the county with the most plan offerings – 87), four firms are offering 10 or more plans (Humana, Blue Cross Blue Shield Affiliates, UPMC Health Plan, and CVS Health). In 125 counties, two firms are offering 10 or more plans, and in 50 counties, three firms are offering 10 or more plans.

In 2025, Humana is increasing the number of plan options available in 631 counties, while decreasing the number of plan options in 1,192 counties. UnitedHealthcare is increasing the number of plans in 381 counties but decreasing plan offerings in 693 counties. Blue Cross Blue Shield Affiliates are increasing the number of plans options in 698 counties, while decreasing plan options in 630 counties. CVS Health is increasing the number of plan options in 667 counties, while decreasing them in 775 counties. This also suggests that insurers evaluate local markets when making decisions about the number of plans to offer and different county characteristics may make the market more or less attractive in a given year to a particular insurer.

Plan Renewals and Terminations

In 2025, 5% of Medicare Advantage enrollees in MA-PDs or about 1.4 million people, are in a plan that has been terminated for the coming year and will not be automatically assigned to another plan. (This number includes people enrolled in SNPs but excludes people in MA-only plans or people with employer coverage). People in this group will be able to enroll in another Medicare Advantage plan if one is available or choose traditional Medicare. If they choose traditional Medicare, they will qualify for a special enrollment period for Medigap with guaranteed issue rights, meaning they can switch to traditional Medicare and will not be denied a Medigap policy due to a pre-existing condition.

Another 7% of Medicare Advantage enrollees in MA-PDs or about 1.8 million people, are in plans that have been affected by a consolidation. In this situation, some portion of this 1.8 million people will be moved into another plan under the same insurer automatically if the contract includes another plan of the same type (i.e., HMO or PPO) in the same county. (Some enrollees in consolidated renewal plans will not see changes in their plan because they were already in the plan that other enrollees are now being assigned to.) They may still enroll in another Medicare Advantage plan if one is available or choose traditional Medicare. However, they do not qualify for a special enrollment period under federal law for Medigap.

New Market Entrants and Exits

In 2025, three firms (Healthy Mississippi, SECUR Health Plan and UCLA Health Medicare Advantage plan) entered the market for the first time, while eight firms exited the market (Appendix Table 2). Healthy Mississippi has one new HMO plan available for general enrollment in Mississippi, while UCLA Health is offering two HMO plans available for general enrollment in California. SECUR Health Plan is offering two I-SNPs in Florida.

In the last few years, some firms have introduced plans that are either co-branded or are in partnership with another company. For example, in 2025, Alignment Health is offering three plans co-branded with Instacart in 7 counties in California and Nevada. These plans will offer groceries to qualifying beneficiaries with chronic conditions. Alignment Health also partners with Walgreens and Rite Aid. Other companies with a partnership that are offering plans in 2025 include Select Health and Kroger and Humana and USAA though this is not an exhaustive list.

Eight firms that participated in the Medicare Advantage market in 2024 are not offering plans in 2025. Six of the firms had low enrollment in 2024 (around 10,000 or fewer enrollees per firm). Two of the firms had contracts taken over by other insurers.

Meredith Freed, Jeannie Fuglesten Biniek, and Tricia Neuman are with KFF. Anthony Damico is an independent consultant.

Methods

This analysis focuses on the Medicare Advantage marketplace in 2025 and trends over time. The analysis of plan offerings, availability of plans by state, county, firm, and insurer are based on individual Medicare Advantage plans for general enrollment. In addition to the analysis of SNP availability, SNPs are also included in counts of plan terminations and renewals as well as entries and exits. Employer plans are excluded from this analysis.

Data on Medicare Advantage plan availability, enrollment, and premiums were collected from a set of data files released by the Centers for Medicare & Medicaid Services (CMS):

  • Medicare Advantage plan landscape files, released each fall prior to the annual enrollment period
  • Medicare Advantage contract/plan/state/county level enrollment files, released on a monthly basis
  • Medicare Advantage plan benefit package files, released quarterly
  • Medicare Enrollment Dashboard files, released on a monthly basis

Connecticut is excluded from the analysis of Medicare Advantage at the county level due to a change in FIPS codes that are in the Medicare Enrollment Dashboard data but are not yet reflected in the Medicare Advantage enrollment data. Some Alaskan counties are also excluded due to differences in FIPS codes.

In previous years, KFF had calculated the share of Medicare beneficiaries enrolled in Medicare Advantage by including Medicare beneficiaries with either Part A and/or B coverage. We modified our approach in 2022 to estimate the share enrolled among beneficiaries eligible for Medicare Advantage who have both Medicare Part A and Medicare B. These changes are reflected in all data displayed trending back to 2010.

Additionally, in previous years, KFF had used the term Medicare Advantage to refer to Medicare Advantage plans as well as other types of private plans, including cost plans, PACE plans, and HCPPs. However, cost plans, PACE plans, HCPPs are excluded from this analysis in addition to MMPs. These exclusions are reflected in all data displayed trending back to 2010.

KFF’s plan counts may be lower than those reported by CMS and others because KFF uses overall plan counts and not plan segments. Segments generally permit a Medicare Advantage organization to offer the “same” local plan, but may vary supplemental benefits, premium and cost sharing in different service areas (generally non-overlapping counties).

Appendix

Fewer Medicare Advantage Plans Are Available in 2025 Than in 2024
Availability of Medicare Advantage Plans and Insurers, by State, 2025
Entrants and Exiting Insurers in Medicare Advantage Markets, by Plan Type and Plan Locations, 2025

Medicare Advantage 2025 Spotlight: A First Look at Plan Premiums and Benefits

Authors: Meredith Freed, Jeannie Fuglesten Biniek, Anthony Damico, and Tricia Neuman
Published: Nov 15, 2024

Note: This analysis was updated on November 25th to reflect the October version of the 2025 CMS Landscape file.

Medicare Advantage plans, which enrolled nearly 33 million Medicare beneficiaries or 54% of the eligible Medicare population in 2024, because they typically offer extra benefits, such as dental, vision and hearing, often for no additional premium, as well as lower cost sharing compared to traditional Medicare without supplemental insurance, with the trade-off of more restrictive provider networks and greater use of cost management tools, such as prior authorization.

This brief provides an overview of premiums and benefits in Medicare Advantage plans that are available for 2025 and key trends over time. This brief uses data from the CMS Landscape and Benefit files. See methods for more details. In general, this brief refers to Medicare plans available for general enrollment, excludes Special Needs Plans (SNPs), except where noted, and excludes employer plans. A companion analysis describes trends in plan offerings.

Medicare Advantage Highlights for 2025

  • Two-thirds of all Medicare Advantage plans with Part D prescription drug coverage (MA-PDs) (67%) will charge no premium (other than the Part B premium) in 2025, similar to 2024 (66%).
  • Nearly one-third (32%) of Medicare Advantage plans will offer some reduction in the Medicare Part B premium in 2025, an increase compared to 2024 (19%).
  • Nearly all Medicare Advantage plans (97% or more) are offering vision, dental and hearing, as they have in previous years. However, the share of plans offering certain benefits has declined, such as over-the-counter benefits (85% in 2024 vs. 73% in 2025), remote access technologies (74% in 2024 vs. 53% in 2025), meal benefits (72% in 2024 vs. 65% in 2025) and transportation (36% in 2024 vs. 30% in 2025).
  • The share of Special Needs Plans (SNPs) offering transportation, remote access technologies and in-home support services declined slightly in 2025, while the share offering bathroom safety devices and the Part B rebate increased.
  • A larger share of SNPs than other Medicare Advantage plans are offering Special Supplemental Benefits for the Chronically Ill, which are extra benefits available to a subset of a plan’s enrollees, particularly food and produce (84% in SNPs; 15% in individual plans) and general supports for living, such as housing and utilities (67% in SNPs; 11% in individual plans).

Premiums

The vast majority of Medicare Advantage plans for individual enrollment (88%) will include prescription drug coverage (MA-PDs), similar to 2024 (89%), and the share of MA-PDs that charge no premium (other than the Part B premium of $185 per month) is 67% in 2025, similar to 2024 (66%). Nearly all beneficiaries (99%) have access to a MA-PD with no additional monthly premium in 2025, the same as in 2024 (99%).

In 2024, 75% of enrollees in MA-PD plans pay no premium other than the Medicare Part B premium. Based on enrollment in March 2024, 10% of enrollees pay at least $50 a month, including 3% who pay $100 or more. CMS estimates that the average monthly plan premium among all Medicare Advantage enrollees in 2025, including those who pay no premium for their Medicare Advantage plan, will be $17.00 a month. In 2024, 12 percent of Medicare Advantage enrollees are in a plan that offered some reduction in Medicare Part B premiums.

In 2025, 32% of Medicare Advantage plans will offer some reduction in the Part B premium, higher than the share in 2024 (19%) (Figure 1).

Among the 32% of Medicare Advantage Plans Offering a Reduction in the Part B Premium, More Than a Quarter (28%) Will Offer a Reduction of $100 a Month or More

Among plans that are offering a monthly reduction in the Part B premium ($185 per month in 2025), 28% are offering a monthly reduction of $100 or more, 25% are offering a reduction of $50.01 to $100, 17% are offering a reduction of $10.01 to $50, and 30% are offering a monthly reduction of $10 or less.

In previous years, a smaller share of Medicare Advantage enrollees has typically ended up in plans that reduced the Part B premium. For example, for the 2024 plan year, 19% of plans offered a reduction in the Part B premium, but ultimately only 12% of Medicare Advantage enrollees were enrolled in plans with this benefit.

While many employers and unions also offer Medicare Advantage plans to their retirees, no information about these 2025 plan offerings is made available by CMS to the public during the Medicare open enrollment period. Employer and union plans are administered separately and may have enrollment periods that do not align with the Medicare open enrollment period.

Extra Benefits

Medicare Advantage plans may provide extra benefits that are not available in traditional Medicare, are considered “primarily health related,” and can use rebate dollars (including bonus payments) to help cover the cost of these extra benefits. Beginning in 2019, CMS expanded the definition of “primarily health related” to allow Medicare Advantage plans to offer additional supplemental benefits. Medicare Advantage plans may also restrict the availability of these extra benefits to certain subgroups of beneficiaries, such as those with diabetes or congestive heart failure, making different benefits available to different enrollees.

Availability of Extra Benefits in Individual Plans for General Enrollment. In 2025, 97% or more individual plans offer some vision, dental or hearing benefits, similar to 2024 (Figure 2). Though these benefits are widely available, the scope of coverage for these services varies. For example, a dental benefit may include cleanings and preventive care or more comprehensive coverage, and often is subject to an annual dollar cap on the amount covered by the plan. From year to year, plans may change the parameters of this coverage, such as increasing or decreasing annual maximums the plan will pay toward the benefit or adjusting cost sharing for services. There is not yet data available about utilization of these benefits or associated costs, so it is not clear the extent to which supplemental benefits are used by enrollees.

The Share of Individual Medicare Advantage Plans Offering Vision, Hearing, and Dental Benefits Stayed Stable in 2025, But Declined for Some Benefits, Such as Over the Counter, Meal, Remote Access Technologies, and Transportation Benefits

As of 2020, Medicare Advantage plans have been allowed to include telehealth benefits as part of the basic benefit package – beyond what was allowed under traditional Medicare prior to the COVID-19 public health emergency, which was extended to December 2024. Therefore, these benefits are not included in the figure above because their cost is not covered by either rebates or supplemental premiums. Medicare Advantage plans may also offer supplemental telehealth benefits via remote access technologies and/or telemonitoring services, which can be used for those services that do not meet the requirements for coverage under traditional Medicare or the requirements for the telehealth benefits as part of the basic benefit package (such as the requirement of being covered by Medicare Part B when provided in-person). In 2025, 53% of plans are offering remote access technologies, a decline from 74% in 2024. A similar share of plans are offering telemonitoring services (2% in 2025 vs 3% in 2024).

Some benefits are being offered by a smaller share of plans in 2025 than in 2024. For example, 73% of plans are offering an allowance for over-the-counter items (vs. 85% in 2024), while 65% are offering meal benefits (vs. 72% in 2024), and 30% are offering transportation benefits for medical needs (vs. 36% in 2024). A similar share of plans is offering acupuncture (32% in 2025 vs. 34% in 2024), bathroom safety devices (24% in 2025 vs 22% in 2024), and support for caregivers of enrollees (5% in 2025 and 2024). A smaller share of plans are offering in-home support services (6% in 2025 vs 9% in 2024). This is not an exhaustive list of extra benefits that plans offer, and plans may provide other services such as home-based palliative care, therapeutic massage, and adult day health services, among others.

Access to Medicare Advantage Plans with Extra Benefits. Virtually all Medicare beneficiaries live in a county where at least one Medicare Advantage plan available for general enrollment (excluding SNPs) has some extra benefits not covered by traditional Medicare, with over 99% having access to at least one or more plans with dental, fitness, vision, and hearing benefits for 2025, the same as in 2024. The vast majority of beneficiaries also have access to one or more plans that offer an allowance for over-the-counter items (over 99%), a meal benefit (over 99%), remote access technologies (99%), acupuncture (98%), bathroom safety devices (96%), transportation assistance (94%) but fewer have access to one or more plans that offer in-home support services (60%), caregiver support (41%), or telemonitoring services (16%).  (Connecticut is not included in these estimates – see methods for more details.)

Availability of Extra Benefits in Special Needs Plans. SNPs are designed to serve a disproportionately high-need population, and a somewhat larger percentage of SNPs than plans for other Medicare beneficiaries provide their enrollees over-the-counter benefits (92%; similar to 2024 – 94%), transportation benefits for medical needs (81%; a decline from 88% in 2024), meals (73%, similar to 2024 – 75%), bathroom safety devices (54%; up from 34% in 2024), and in-home support services (17%; down from 25% in 2024) (Figure 3). Compared to individual plans, a smaller share of SNPs offer fitness benefits (83%, similar to 2024 – 84%), remote access technologies (50%; a decline from 66% in 2024), and the Part B rebate (29%; up from 7% in 2024). Similar to plans available for individual enrollment, a relatively small share of SNPs offer support for caregivers (5%) or telemonitoring services (2%).

The Share of Special Needs Plans (SNPs) Offering Vision, Hearing, and Dental Benefits Stayed Stable in 2025, But Declined for Some Benefits, Such as Transportation Benefits, Remote Access Technologies, and In-Home Support Services, And Increased For Others, Such as Bathroom Safety Devices and the Part B Rebate

Availability of Special Supplemental Benefits for the Chronically Ill (SSBCI). Beginning in 2020, Medicare Advantage plans have also been able to offer extra benefits to a subset of a plan’s enrollees, that are not primarily health related and are specifically for chronically ill beneficiaries, known as Special Supplemental Benefits for the Chronically Ill (SSBCI). In addition, Medicare Advantage plans participating in the Value-Based Insurance Design Model may also offer these non-primarily health related supplemental benefits to their enrollees, but can use different eligibility criteria than required for SSBCI, including offering them based on an enrollee’s socioeconomic status (e.g., LIS eligibility) or whether the enrollee lives in an underserved area.

Most individual and SNP Medicare Advantage plans still do not offer these benefits, though more SNP plans generally offer these benefits, particularly food and produce. SSBCI benefits offered in 2025 include food and produce (15%% for individual plans and 84% for SNPs), general supports for living (e.g., housing, utilities) (11% in individual plans and 67% for SNPs), transportation for non-medical needs (8% for individual plans and 46% for SNPs), and pest control (3% for individual plans and 23% for SNPs) (Figure 4).

Most Medicare Advantage Plans Are Not Offering Special Supplemental Benefits for the Chronically Ill (SSBCI) in 2025, Similar to Prior Years, Though More SNPs Generally Offer These Benefits

Like for other types of supplemental benefits, the scope of services for SSBCI benefits varies. For example, many plans offer a specified dollar amount that enrollees can use toward a variety of benefits, such as food and produce, utility bills, rent assistance, and transportation for non-medical needs, among others. This dollar amount is often loaded onto a flex card or spending card that can be used at participating stores and retailers, which can vary depending on the vendor administering the benefit. Depending on the plan, this may be a monthly allowance that expires at the end of each month or rolls over month to month until the end of the year, when any unused amount expires.

Meredith Freed, Jeannie Fuglesten Biniek, and Tricia Neuman are with KFF. Anthony Damico is an independent consultant.

Methods

This analysis focuses on the Medicare Advantage marketplace in 2025 and trends over time.Data on Medicare Advantage plan availability, enrollment, and premiums were collected from a set of data files released by the Centers for Medicare & Medicaid Services (CMS):

  • Medicare Advantage plan landscape files, released each fall prior to the annual enrollment period- Medicare Advantage plan crosswalk files, released each fall
  • Medicare Advantage contract/plan/state/county level enrollment files, released on a monthly basis
  • Medicare Advantage plan benefit package files, released quarterly
  • Medicare Enrollment Dashboard files, released on a monthly basis

Connecticut is excluded from the Access to Medicare Advantage Plans with Extra Benefits section of this analysis due to a change in FIPS codes that are in the Medicare Enrollment Dashboard data but are not yet reflected in the Medicare Advantage enrollment data. Some Alaskan counties are also excluded due to differences in FIPS codes.

In previous years, KFF had calculated the share of Medicare beneficiaries enrolled in Medicare Advantage by including Medicare beneficiaries with either Part A and/or B coverage. We modified our approach in 2022 to estimate the share enrolled among beneficiaries eligible for Medicare Advantage who have both Medicare Part A and Medicare B. These changes are reflected in all data displayed trending back to 2010.

Additionally, in previous years, KFF had used the term Medicare Advantage to refer to Medicare Advantage plans as well as other types of private plans, including cost plans, PACE plans, and HCPPs. However, cost plans, PACE plans, HCPPs are excluded from this analysis in addition to MMPs. These exclusions are reflected in all data displayed trending back to 2010.

KFF’s plan counts may be lower than those reported by CMS and others because KFF uses overall plan counts and not plan segments. Segments generally permit a Medicare Advantage organization to offer the “same” local plan, but may vary supplemental benefits, premium and cost sharing in different service areas (generally non-overlapping counties).

 

VOLUME 10

Distrust in Food Safety and Social Media Content Moderation

This is Irving Washington and Hagere Yilma. We direct KFF’s Health Misinformation and Trust Initiative and on behalf of all of our colleagues across KFF who work on misinformation and trust we are pleased to bring you this edition of our bi-weekly Monitor.


Summary

This volume addresses rising distrust in food safety, as concerns about food recalls after potential listeria outbreaks and artificial food dyes erode trust in the USDA and the FDA. We also examine shifts in social media content moderation, highlighting the tension between regulating harmful misinformation and protecting First Amendment rights in the recent elections, and the trend of self-diagnosis and treatment based on social media videos.


Recent Developments

A Growing Distrust in Food Safety May Give Rise to Misinformation

erierika / Getty Images

Concerns about artificial dyes in the food supply have recently gained traction, with growing public suspicion that these dyes contribute to health problems, such as ADHD in children and other chronic diseases into adulthood. Protests at Kellogg’s headquarters and the recent California law banning six of these dyes in school meals reflect increasing public concern, especially among parents. While some studies suggest that synthetic food dyes may be linked to adverse health effects, the FDA currently deems these dyes safe for consumption at the levels used in foods, leading some to question the agency’s standards. Robert F. Kennedy Jr.’s “Make America Healthy Again” campaign, which promised to “clean up” the FDA and other public health agencies, tapped into this distrust and may have resonated with those who feel the FDA is no longer a reliable authority on food safety.

Recent food recalls have also fueled misconceptions about food safety, with some social media posts falsely claiming that government agencies are intentionally “poisoning” the U.S. food supply to spread illness. This response followed the USDA’s October 9 recall of millions of pounds of ready-to-eat meat potentially contaminated with listeria. In the month following the recall, mentions of food safety concerns surged in news articles and on social media, with about 1 million mentions overall and 19,000 specific mentions of BrucePac. The most widely viewed post on X, posted on October 16 and receiving over 439,000 views, alleged that “elites” and the FDA are deliberately contaminating food with bacteria, GMOs, and heavy metals. Many commenters echoed the unsubstantiated claim that government agencies and corporations are “intentionally poisoning” the public, despite recalls being triggered by FDA safety violations. The reemergence of unverified claims about food safety underscores the challenge of addressing public concerns in an environment where misinformation can quickly spread and influence perceptions.

Unregulated Health Advice on Social Media Promotes Self-Diagnosis and Treatment of Health Conditions

RossHelen / Getty Images

Social media has increasingly become a platform for deceptive health and wellness advertisements, sometimes using deepfake technology to feature celebrities or scientists endorsing non-FDA-approved products. From over-the-counter hearing aid scams to fake insomnia pills, unregulated and potentially dangerous medical products misrepresented to the public can confuse consumers about the safety of these treatments. Unverified rumors about health and wellness can also come from social media users who share their personal experiences navigating health and wellness. These posts are often motivated by a desire to help or connect with others, but some influential users stand to financially benefit from promoting false or misleading information about health behaviors or wellness products. Regardless of intent, false, unverified, or misleading information shared in viral videos has led to an increase in self-diagnosis and treatment of health conditions.

One example is the growing trend of self-diagnosing mental health conditions on social media, particularly on platforms like TikTok. Some users claim to have been misdiagnosed or overlooked by healthcare providers, fueling their desire to share their experiences online. Influencers with large followings and personal brands often contribute to this trend, sometimes in pursuit of financial or social gain. This can create a cycle of content that encourages self-diagnosis and the use of non-FDA-approved or non-prescribed treatments. While social media content may be seen as quick and accessible advice when professional mental health care is difficult to access, research shows that many popular mental health videos contain misleading or oversimplified information, potentially leading users to misinterpret common symptoms as serious conditions such as ADHD or anxiety. Psychologists warn that self-diagnosis based on such content can overlook complex causes or lead to inappropriate treatment attempts. Some experts suggest that educational psychologists can combat misinformation in this area by working with young people and sharing evidence-based content on platforms like TikTok.

Polling Insights:

KFF’s May Health Information Tracking Poll found that most adults who use TikTok report seeing health-related content on the app. While four in ten TikTok users say they trust the information about health issues they see on TikTok at least “somewhat,” far fewer say they have ever talked to a doctor (13%) or sought mental health treatment (12%) because of something they saw on the app (Figure 1). Among adults who use TikTok, those who are younger, women, or daily users are more likely to say they’ve talked to a doctor or sought mental health treatment at least in part because of something they saw on the app. Nonetheless, across these demographics, most users say they have not followed up with a doctor or sought mental health treatment due to content they’ve seen on TikTok.

Four in Ten TikTok Users Say They Trust Information About Health Issues on TikTok, But Few Say They Have Ever Talked to a Doctor or Sought Mental Health Treatment Because of Something They Saw on the App

Elections Spark Ongoing Content Moderation Challenges for Social Media Companies

gorodenkoff / Getty Images

The way social media companies handled harmful information leading up to the recent election has had a lasting impact on debates about balancing content moderation with First Amendment rights. Social media companies have been under scrutiny for failing to remove false or misleading election-related posts, but efforts to take down potentially harmful content often lead to accusations of censorship. For example, Meta faced criticism from its oversight board for stifling political speech when it removed a post depicting Vice President Kamala Harris and former running mate Governor Tim Walz as characters from the movie Dumb and Dumber.

A broader Republican-led narrative suggesting that the federal government is being weaponized to censor conservative viewpoints has further politicized terms like “misinformation” and created distrust in government efforts to identify and reduce harmful information on social media. As a result, even government efforts to increase transparency around content moderation also face resistance from platforms. This was seen in California, where a lawsuit brought by Elon Musk claims that the state violated free speech by requiring social media companies to publicly disclose their content moderation policies. Concerns about restrictions on free speech on social media were central to several cases the Supreme Court considered this year, but the Court did not provide definitive guidance on how moderation affects First Amendment rights.

These ongoing tensions between platforms, politicians, and regulators suggest that finding the balance between free speech and content moderation will likely remain one of social media’s most contentious challenges, leaving a murky area for future policy efforts.


Research Insights

Equipping TikTok Influencers with Training Boosts Accurate Mental Health Communication

mapodile / Getty Images

A study published in Scientific Reports earlier this year explored how TikTok influencers can be encouraged to share evidence-based mental health information, with the aim of improving mental health communication on the platform. The researchers found that TikTok creators who were provided with digital toolkits and optional live training sessions were more likely to produce videos with accurate mental health information. Creators who used these resources also saw a boost in viewership of their mental-health related videos, suggesting that scalable training for influencers can combat misinformation in a manner acceptable to viewers.

Source: Motta, M., Liu, Y., & Yarnell, A. (2024). “Influencing the influencers:” a field experimental approach to promoting effective mental health communication on TikTok. Scientific Reports, 14(1), 5864.

Personal Role Models on Social Media Drive Stronger Health Motivation Through Relatability

A study in Health Communication examined how personal and entertainment role models influence people’s health motivation, particularly through social media. The researchers found that people who followed someone on social media that they consider a role model have stronger health motivations, with personal role models, like family and friends, having a greater impact on health goals than entertainment figures. Among the qualities that made role models effective in motivating health behaviors, the researchers found that perceived similarity was the strongest, as people felt more inspired by role models who seemed relatable. The findings suggest that health campaigns should leverage personal connections and relatable influencers to inspire healthier behaviors.

Source: O’Donnell, N. H., Erlichman, S., & Nickerson, C. G. (2024). Health Motivation in the Influencer Era: Analyzing Entertainment, Personal, and Social Media Role Models. Health Communication, 1-12.


AI and Emerging Technology

Study Finds Low Trust in AI for Health Information Among Older Adults

Laurence Dutton / Getty Images

While some have found beneficial uses for AI in health information, such as debunking conspiracy theories or providing quick, low-stakes health advice, a significant portion of the population remains skeptical. A University of Michigan National Poll on Healthy Aging found that nearly three-quarters of adults over 50 have little to no trust in AI-generated health information. This distrust is particularly pronounced among women, individuals with lower education or income, and those who haven’t recently seen a healthcare provider. Additionally, 20% of respondents reported low confidence in identifying health misinformation. Older adults in poorer physical or mental health faced even greater challenges in finding accurate information. The findings from this report suggest a gap in health literacy among older adults that can be addressed by health professionals.

About The Health Information and Trust Initiative: the Health Information and Trust Initiative is a KFF program aimed at tracking health misinformation in the U.S., analyzing its impact on the American people, and mobilizing media to address the problem. Our goal is to be of service to everyone working on health misinformation, strengthen efforts to counter misinformation, and build trust. 


View all KFF Monitors

The Monitor is a report from KFF’s Health Information and Trust initiative that focuses on recent developments in health information. It’s free and published twice a month.

Sign up to receive KFF Monitor
email updates


Support for the Health Information and Trust initiative is provided by the Robert Wood Johnson Foundation (RWJF). The views expressed do not necessarily reflect the views of RWJF and KFF maintains full editorial control over all of its policy analysis, polling, and journalism activities. The Public Good Projects (PGP) provides media monitoring data KFF uses in producing the Monitor.


What Administrative Changes Can Trump Make to Medicaid?

Published: Nov 8, 2024

With Donald Trump returning to the presidency, the future of Medicaid is uncertain. While Medicaid did not receive a lot of attention directly during the campaign, Trump’s first term can shed light on potential changes that could be implemented administratively without Congress.

1. Trump administration could encourage and approve Medicaid waivers to advance priorities, including work requirements.

The previous Trump administration’s Section 1115 waiver policy emphasized work requirements, other eligibility restrictions, and capped financing. The Trump administration approved 13 waivers that allowed states to condition Medicaid eligibility on meeting work and reporting requirements and also approved waivers that restricted eligibility, including by permitting states to charge premiums and lock out enrollees who are disenrolled for unpaid premiums. Although previous work requirements in Medicaid were challenged in court and the waivers imposing work requirements were rescinded by the Biden administration, a number of states continue to be interested in adopting them. Although CMS withdrew work and premium requirements in Georgia’s “Pathways” waiver, these provisions remain in place after a federal judge vacated the CMS rescission.

Trump also introduced a demonstration opportunity, the “Healthy Adult Opportunity” (HAO), that would have allowed states “extensive flexibility” to use Medicaid funds to cover certain adults – including those who qualify under the Affordable Care Act’s expansion — without being bound by federal standards related to eligibility, benefits, delivery systems, and oversight in exchange for annual limits on federal financing. While no state took up this option during the first administration, these waivers restructure Medicaid financing in ways similar to block grant and per capita cap proposals and promoting the waivers in a second administration would enable Trump to advance that policy even in the absence of Congressional action. However, unlike legislative proposals that would alter Medicaid financing and significantly cut federal spending, it is unlikely that states would opt for such deals if federal financing would be cut significantly.

The new Trump administration’s waiver priorities will differ significantly from those of the Biden administration and it is unclear how the Trump administration will treat certain waivers promoted and approved by the Biden administration, such as those focused on addressing health-related social needs, multi-year continuous eligibility, and leveraging Medicaid to help individuals leaving incarceration transition to the community. The Trump administration could choose not to approve waivers that remain pending, rescind existing waiver guidance, or withdraw approved waivers, although some of these waivers, particularly ones using Medicaid to assist with reentry from incarceration, have been pursued by both Republican and Democratic governors.

2. Trump administration could choose not to implement or rewrite recent regulations.

The Biden administration finalized a number of major Medicaid regulations designed to promote quality of care and advance access to care for Medicaid enrollees as well as to streamline eligibility and enrollment processes in Medicaid and the Children’s Health Insurance Program (CHIP).

  • The Access rule addresses several dimensions of access: increasing provider rate transparency and accountability, standardizing data and monitoring, and creating opportunities for states to promote active enrollee engagement in their Medicaid programs. The rule also included many provisions governing access to home care (also known as home- and community-based services or HCBS), which include ensuring that at least 80% of spending on certain services be spent on compensation for direct care workers and requiring states to report the number of people on waiting lists for care.
  • The Managed Care rule addresses Medicaid managed care access, financing, and quality, including strengthening standards for timely access to care and states’ monitoring and enforcement efforts.
  • The Long-Term Care Facility (LTC) Staffing rule requires minimum staffing standards for nursing facilities.
  • Two rules streamline Medicaid enrollment and renewal processes for the Medicare Savings Program (MSP) and for Medicaid, CHIP and the Basic Health Program. The first rule helps eligible Medicare beneficiaries more easily access Medicaid coverage of Medicare premiums and cost sharing through the MSP while the second rule simplifies application, enrollment, and renewal processes and removes access barriers for children in CHIP. Each rule is expected to increase Medicaid enrollment by about one million people.

These rules are complex and are set to be implemented over several years. The Trump administration could delay implementation of certain provisions, which would reduce regulation of managed care companies, nursing facilities, and other providers, while rolling back enrollee protections, payment transparency, and improved access. Alternatively, the Trump administration could issue new regulations that would undo these final regulations.

3. Trump administration could issue guidance and implement policy to make it more difficult for people to obtain and maintain coverage, reducing enrollment and spending.

The Trump administration could also issue sub-regulatory guidance to change eligibility or renewal policies to restrict coverage by tightening verification of eligibility. Previously, the Trump administration sought to reduce Medicaid enrollment by encouraging states to conduct eligibility verification processes in between annual renewal periods. While some states conduct these periodic data checks, the administration could encourage more states to adopt the policy as a program integrity strategy. The Trump administration could also eliminate flexibilities granted under the Biden administration that allow states to streamline renewal procedures. Getting rid of these flexibilities would likely make it harder for some enrollees to renew their Medicaid coverage, while providing greater certainty that people who are ineligible do not obtain coverage.

Beyond waivers, regulations, and enrollment policy, if the Republicans gain control of both the House and the Senate, Trump could work with Congress to enact legislation that would more fundamentally change the financing structure of Medicaid and make significant cuts to federal Medicaid spending, similar to policies Trump has supported in the past.

News Release

Abortion Was a Motivating Factor for Many Voters in Tuesday’s Election But Ranked Lower Than Concerns About the Economy

Dashboard Highlights Abortion and Health Costs Insights from AP VoteCast Survey, Including Data from Supplemental KFF Questions

Published: Nov 6, 2024

Abortion drove many voters to turn out for Tuesday’s election, but not always for Vice President Kamala Harris, while concerns about the economy weighed more heavily on voters’ minds, according to polling data from KFF and the Associated Press.

About a quarter of voters said abortion was the “single most important” factor in their vote, about 4 in10 said it had a major impact on their decision to turn out (similar to the shares who said so in the 2022 midterm elections), and over half said it had a major impact on which candidates they supported, according to the Associated Press’s VoteCast survey. In partnership with the AP, KFF added supplemental questions to the survey of the 2024 electorate to gauge how voters were weighing health care issues as they exited the polls.

But Vice President Harris’s strong advantage on abortion was not enough to override negative views of the economy and immigration, issues where President- Elect Donald Trump held the edge, the polling data shows. Forty percent of voters said high prices for gas, groceries and other goods was the single most important factor to their vote, including 51% of Republicans, 41% of independents, and 28% of Democrats.

KFF’s analysis shows that Trump did much better than Harris among the majorities of voters who reported being very concerned about the cost of groceries, gas, and housing. He also did better than Harris among the more than half of voters who said they were very concerned about the cost of health care.

Moreover, on the issue of abortion, Trump managed to garner small but important shares of votes among those who voted in favor of abortion ballot measures in their state, winning four states where voters also chose to expand or protect abortion access. Trump won support from about three in ten voters who voted in favor of abortion access in the battleground states of Nevada and Arizona, a similar share in Missouri, and about a quarter in Montana.

In an online interactive dashboard, KFF examines the role that abortion, the economy and health care costs played in the 2024 election, providing a deep dive into voters’ thinking on health care issues as they made their decisions about whether to vote and whom to vote for.

KFF provides data and analysis of the overall AP VoteCast survey and these supplemental questions at both the national and state level.

The dashboard includes:

  • An interactive map that provides a more detailed look at states with abortion-related ballot measures.
  • Analysis and charts examining the motivations of voters and the impact of concerns about abortion policy and health care costs nationally and across states, including some data breakouts by demographic groups and political party.
  • A curated set of charts providing key analysis among subgroups of voters on topics like abortion ballot measures, health care as an economic concern, and voters’ views of the most important issues facing the U.S.

The AP VoteCast is a national and 48 state surveys of more than 115,000 voters conducted by NORC at the University of Chicago for The Associated Press, Fox News, PBS NewsHour, and The Wall Street Journal beginning on Oct. 28 and concluding as polls closed on Nov. 5, 2024, in English and Spanish. The national survey was conducted using NORC’s probability-based AmeriSpeak panel, while the individual state surveys were conducted from a random sample of state voter files and from self-identified registered voters selected from non-probability online panels. More details are available about AP VoteCast’s methodology here.

KFF/AP VoteCast: Abortion and Other Health Care Issues in the 2024 Election

This interactive dashboard provides KFF’s insights from AP VoteCast election polling of the 2024 election, focusing on how abortion, including abortion-related ballot measures, and other health care issues have played into voters’ decisions.

KFF examined the role that abortion policy and abortion-related state ballot initiatives, as well as the economy and health care costs, played in the 2024 election. In partnership with The Associated Press (AP), KFF added supplemental questions to AP VoteCast, a survey of the 2024 electorate, providing a deep dive into how voters were weighing health care issues as they made their decisions. These questions and KFF’s analysis shed light on the role these issues played in shaping the concerns voters brought to the ballot box, as well as their decisions about whether to vote and whom to vote for.

For additional analysis, see KFF’s full report: The Role Health Care Issues Played in the 2024 Election: An Analysis of AP VoteCast

AP VoteCast is a survey of nearly 120,000 voters conducted nationally and in 48 states, fielded between Oct. 28 and concluding as the polls close on Nov. 5. Results have been adjusted to reflect preliminary vote totals as of 10 a.m. ET on Nov. 11, 2024. 

Updated: November 22, 2024 4:00PM ET

KFF Analysis of AP VoteCast

Abortion Ballot Initiatives

Copy link to Abortion Ballot Initiatives

In the 2024 election, 10 states voted on ballot measures aimed at protecting abortion rights, including one state (Nebraska) whose ballot also included a competing measure curtailing abortion rights. Voters in seven states voted to expand abortion access, while the ballot measures to expand abortion access failed in Florida, South Dakota, and Nebraska. More details about the different state ballot measures are available at this KFF Ballot Tracker.

About half of voters in each of these states said the outcome of the abortion ballot initiative was “very important” to them. In all 10 states, more than half of those who voted in favor of protecting abortion access said the outcome of the measure was “very important” to them. In most states, proponents of abortion access were more likely than opponents to say the outcome was very important.

Voters in South Dakota and Nebraska voted against expanding abortion access in their states. In both of those states, a majority of voters on both sides of the ballot measure viewed its outcome as “very important” – suggesting that supporters and opponents were similarly motivated by the measures’ results. In Florida, the ballot measure failed to reach the 60% threshold needed in order to pass. About six in ten Florida voters who voted in favor of expanding abortion access said the outcome of the ballot measure was important to them compared to about half of voters who opposed the measure.

Abortion-Related State Constitutional Amendment Measures in the 2024 General Election
A Majority of Voters Who Favored Protections for Abortion Access Said The Initiatives In Their States Were Important to Them; Fewer of Those Who Opposed Said They Were Important

In each of the states where abortion was on the ballot in 2024, about one in four voters said abortion was the single most important issue to their vote, similar to the share of voters nationally who said so. About four in ten voters in these states said abortion policy had a “major impact” on whether they voted, and more than half said it had a major impact on which candidates they supported this election.

Across States With Abortion on The Ballots, About One in Four Voters Said Abortion Was the Most Important Factor in Their Vote; At Least Half Said Abortion Had an Impact on Who They Supported

President-elect Donald Trump won key electoral victories in four states where voters also chose to expand or protect abortion access: Arizona, Nevada, Montana and Missouri. Across all ten states with abortion ballot measures, Trump garnered small but important shares of votes from those who voted in favor of ballot measures protecting abortion access, including support from about three in ten of those who voted in favor of abortion access in Missouri and Montana and in the battleground states of Nevada and Arizona.

In States With Abortion on the Ballot, Notable Share of Those Who Voted to Protect Abortion Rights Also Voted for Trump

Arizona and Nevada: Key Swing States with Abortion Ballot Initiatives

Arizona and Nevada are two battleground states where President-elect Trump won at the same time as a majority of voters passed ballot measures expanding abortion access.  

Arizona’s Proposition 139 passed with a majority of voters voting “Yes.” It proposed enshrining the right to abortion in the state constitution, allowing abortion until fetal viability or at any stage in cases where the pregnant person’s health or life is at risk. This ballot measure will codify protections similar to those under Roe v. Wade before it was overturned. Arizona law currently bans abortions after 15 weeks. This proposition was supported by a majority of voters in the state across age, gender, race, and ethnicity. The vast majority of Democratic Arizona voters and those who voted for Kamala Harris voted Yes on the proposition. Most Republicans and those who voted for Donald Trump voted against the proposition, yet about four in ten in both groups voted in favor of the measure.

AZ BALLOT1 + IMPTBALLOT
AZ imptabortion turnout cand

Nevada’s ballot featured the Right to Abortion Initiative, Question 6, which sought to affirm a constitutional right to abortion up to fetal viability and after viability in cases where the pregnant person’s life or health is endangered. The measure passed receiving support from over nine in ten Nevada Democrats and those who voted for Harris, as well as nearly half of Republicans and those who voted for Trump.

Ballot measures have to pass in two successive general elections in Nevada. This measure will have to appear on the ballot again in 2026 before the proposed amendment is added to the Nevada constitution.

NV BALLOT1 + IMPTBALLOT
NV imptabortion turnout cand

Many Arizona and Nevada Voters Voted to Expand Access to Abortion, While Supporting Republican Candidates for Senate and President

Roughly one quarter to one third of voters in Arizona and Nevada who voted “Yes” on their state’s ballot measures to protect access to abortion voted for Republican candidates for senate and Trump for president. The vast majority of those who voted “No” on these measures voted for Republican candidates as well.

AZ Vote Choice by Ballot Measure
AZ Vote Choice by Ballot Measure SEN
NV Vote Choice by Ballot Measure
NV Vote Choice by Ballot Measure SEN

Spotlight on Florida

Amendment 4, the “Florida Right to Abortion Initiative,” failed to meet the 60% vote threshold required to pass. It would have amended the state constitution to enshrine the right to abortion until the point of fetal viability, or to protect the mother’s health. Currently, Florida has a 6-week abortion ban. The passage of Amendment 4 in Florida would have provided a legal pathway to abortion for women in the region currently considered an abortion desert.

While the ballot measure failed to reach 60% support, large majorities of independent and Democratic voters in the state supported it, as did a majority of both men and women and voters across race and ethnicity. While most Republicans and Trump voters opposed the measure, about four in ten Republicans and about a third of those who voted for Trump voted in favor of the proposition.

FL BALLOT1 + IMPTBALLOT
FL imptabortion turnout cand

Spotlight on Nebraska

Nebraska was the only state in this election to have two competing abortion-related ballot measures. One would have established a fundamental right to abortion until fetal viability or when needed to protect the life or health of the pregnant person at any time during pregnancy/. The second measure, which passed, amended the constitution to ban abortions past the first trimester, except in medical emergencies or when the pregnancy is a result of rape or incest. Currently, abortions are legal in Nebraska up to 12 weeks of pregnancy.

Support for the two ballot measures was largely divided along partisan lines, with nine in ten Democrats supporting the Right to Abortion Initiative and about three-quarters of Republicans supporting the measure restricting abortion access. Among independent voters, a larger share supported the measure expanding abortion access than the one restricting abortion access.

NE BALLOT1 + IMPTBALLOT
NE imptabortion turnout cand

Abortion as a Voting Issue

Copy link to Abortion as a Voting Issue

As it was in the 2022 midterm election, abortion continued to be a motivating factor for a notable share of voters in 2024. Overall, about a quarter of voters said abortion was the “single most important” factor to their vote, similar to the share in 2022 who said the Supreme Court overturning Roe v. Wade was the most important factor. In addition, about four in ten voters in 2024 said abortion had a major impact on their decision about whether to turn out, and over half said it had a major impact on which candidates they supported.

For voters overall, abortion ranked behind democracy and inflation as a motivating factor but was on par with “the situation at the U.S.-Mexico border.” Democrats were more than twice as likely as Republicans to say abortion policy was the most important factor to their vote.

Abortion Remains a Motivating Factor Among Voters 
Three in Ten Voters Say Abortion Was the Single Most Important Factor to Their Vote, With Larger Shares Citing High Prices For Essential Goods and the Situation at the U.S.-Mexico Border

The impact of abortion policy on voters’ decisions stood out among certain groups of voters, namely Black voters, younger voters, Democrats, and women – all of whom cited abortion policy as a motivating factor in higher shares than their peers. Additionally, among women voters, large shares of those who are younger, Black, or Democrats cited abortion as the single most important factor to their vote or said it had a major impact on their decision to turnout or the candidate they voted for.

Larger Shares of Women and Black Voters Say Abortion Impacted Their Vote
A Majority of Women Under Age 50 Say Abortion Was the Single Most Important Factor to Their Vote and Had  a Major Impact on Their Decision to Vote and Whom They Voted For
About Three in Ten First Time Voters Say Abortion Was the Most Important Factor to Their Vote
Notable Shares of Republicans Who Voted Harris Say Abortion Policy Was The Most Important Factor Driving Their Vote

VP Harris achieved high levels of support among voters who said abortion was the single most important factor to their vote as well as those who prioritized the future of Democracy. President-elect Trump won a larger share of voters who cited high prices and the U.S.-Mexico border as the most important factors in their vote. While a large majority of voters who said they want abortion to be legal in “all cases” voted for Harris, Trump gained notable support among those who want abortion to be legal in “most cases.”

A Majority of Voters Who Say Abortion Was Their Top Issue Voted Harris, While Most Voters Citing High Prices of Essential Goods Went With Trump
One-Third of Voters Who Say Harris Has a Better Handle of Abortion Policy Nonetheless Voted for Trump

Health Care Costs and Other Issues

Copy link to Health Care Costs and Other Issues

When asked to choose the most important issue facing the country, about four in ten voters chose the economy and jobs, followed by about two in ten who chose immigration. Abortion and health care were next on the list, with about one in ten voters citing each respectively. The economy and jobs topped the list for both Trump voters and Harris voters, with immigration ranking second among Trump voters and abortion ranking second among Harris voters.

With the economy top of mind, health care costs were an integral part of voters’ economic concerns. About half said they were “very concerned” about their own health care costs, with an additional three in ten saying they were “somewhat concerned.” This is somewhat behind the two-thirds of voters who said they were “very concerned” about the cost of food and groceries, and similar to the shares who said they were “very concerned” about the cost of housing and gas. Regardless of partisanship, half or more voters said they were “very concerned” about the cost of these items, with the exception of gas, which generates almost twice as much concern among Republicans as among Democrats.

ISSUES2024option1
BUDGEToption1
BUDGEToption2

When it comes to who voters trust to handle different issues, President-elect Trump had a clear advantage over Vice President Harris on the economy, immigration, and crime with about half of voters favoring Trump on these issues compared to about four in ten choosing Harris. On the other hand, Harris had a clear advantage on abortion policy, health care, and climate change, with about half preferring Harris and between three and four in ten preferring Trump on these issues.

BETTERHAoption3

Despite the fact that Harris had an advantage on who voters trust to handle health care, Trump won a majority of votes among those with the greatest concern about their personal expenses, including half of voters who said they were “very worried” about their own health care costs. Trump also garnered majority support among voters who were very worried about the costs of gas, food, and housing.

Donald Trump Garners Majority Support Among Voters Who Were Most Worried About Personal Economic Expenses

 When asked about the role government should play on key health care issues going forward, the largest share said they want more government action on lowering the price of prescription drugs, with three in four saying the government should be “more involved.” About six in ten also support greater government involvement when it comes to ensuring Americans have health care coverage and forgiving medical debt. Half of voters said the government should be “more involved” in ensuring that children are vaccinated for childhood diseases. On each of these topics, one in five or fewer said the government should be “less involved,” and similar shares said the government’s current involvement is “about right.”

On these topics, there was some partisan agreement, with majorities of Democrats, Republicans, and independents saying the government should be “more involved” in lowering the cost of prescription drugs. However, on the other topics, there were stark partisan divides, with about four in ten or fewer Republicans saying the government should be “more involved” and large majorities of Democrats wanting more involvement.

HEALTHCAREGOVToption1
HEALTHCAREGOVToption2

As of 2024, 41 states (including DC) have adopted Medicaid expansion under the Affordable Care Act while 10 states have not. In three of these non-expansion states, Alabama, Kansas and Mississippi, voters were asked whether they would favor or oppose expanding the program in their state. In each of these states, seven in ten or more voters overall said they would favor expanding Medicaid in their state, including majorities of Democrats and Republicans.

MEDICAID

Methodology and Additional Resources

Copy link to Methodology and Additional Resources

AP VoteCast is a survey of nearly 120,000 voters conducted nationally and in 48 states by NORC at the University of Chicago for The Associated Press, Fox News, PBS NewsHour, and The Wall Street Journal beginning on Oct. 28 and concluding as polls close on Nov. 5, 2024. AP VoteCast conducts interviews with a random sample of registered voters drawn from state voter files and combines them with interviews from self-identified registered voters selected using nonprobability approaches. It also includes interviews with self-identified registered voters conducted using NORC’s probability-based AmeriSpeak panel, which is designed to be representative of the U.S. population. Interviews are conducted in English and Spanish.

Note: Party labels include partisan leaning independents.

Find more details about AP VoteCast’s methodology at https://www.ap.org/content/politics/elections/ap-votecast/about.

For media inquiries contact KFFMedia@kff.org

….

Medicaid Coverage of and Spending on GLP-1s

Published: Nov 4, 2024

GLP-1 (glucagon-like peptide-1) drugs have been used as a treatment for type 2 diabetes for over a decade, but newer forms of these drugs have gained widespread attention for their effectiveness as a treatment for obesity. While these drugs have provided new opportunities for obesity treatment, they have also raised questions about access to and affordability of these drugs. These drugs are expensive when purchased out of pocket, and coverage in Medicaid, ACA Marketplace plans, and most large employer firms remains limited, though a number of state Medicaid programs and other payers are re-evaluating their coverage policies. Expanding Medicaid coverage of these drugs could increase access for the almost 40% of adults and 26% of children with obesity in Medicaid. At the same time, expanded coverage could also increase Medicaid drug spending and put pressure on overall state budgets. In the longer term, however, reduced obesity rates among Medicaid enrollees could also result in reduced Medicaid spending on chronic diseases associated with obesity, such as heart disease, type 2 diabetes, and types of cancer. This brief discusses Medicaid coverage of GLP-1s, examines recent trends in Medicaid prescriptions and gross spending on GLP-1s, and explores the potential implications of expanding coverage obesity drugs for Medicaid programs.

Does Medicaid cover GLP-1s for obesity treatment?

States can decide whether to cover obesity drugs under Medicaid. Under the Medicaid Drug Rebate Program, Medicaid programs must cover nearly all of a participating manufacturer’s Food and Drug Administration (FDA)-approved drugs for medically accepted indications. However, weight-loss drugs are included in a small group of drugs that can be excluded from coverage1 . Though the statutory exception refers to agents used for “weight loss”, “obesity drugs” is used to refer to this group of medications in this analysis. The FDA has approved three GLP-1s for the treatment of obesity, Saxenda (liraglutide), Wegovy (semaglutide), and Zepbound (tirzepatide), and state Medicaid coverage of these is optional. However, Medicaid programs have to cover formulations to treat type 2 diabetes, including Ozempic (semaglutide), Rybelsus (semaglutide), Victoza (lirglutide), and Mounjaro (tirzepatide). Wegovy, as of March 2024, must also be covered for preventing heart attacks or strokes in adults with cardiovascular disease; however, this expanded label indication does not impact this analysis as it only includes data through 2023. Notably, all obesity drugs are covered for children under Medicaid’s Early and Periodic Screening, Diagnostic and Treatment (EPSDT) benefit, though it is less clear how states are implementing and covering in practice.

Obesity drug coverage in Medicaid remains limited, with 13 state Medicaid programs covering GLP-1s for obesity treatment as of August 2024 (Figure 1). Twelve states in KFF’s annual budget survey reported coverage of GLP-1s for obesity treatment under FFS as of July 1, 2024, and North Carolina reported adding coverage in August of 2024. All 12 states that reported coverage of GLP-1s as of July 1, 2024 also reported that utilization control(s) applied, with the most common being prior authorization (11 of 12 states) and/or BMI requirements (11 of 12 states). Eleven of the 12 states reported covering all three GLP-1s currently approved for the treatment of obesity (Saxenda, Wegovy, or Zepbound). While the survey only asked about FFS coverage, MCO drug coverage must be consistent with the amount, duration, and scope of FFS coverage. MCOs, however, may apply differing utilization controls and medical necessity criteria unless the state’s MCO contract specifies otherwise. Coverage among other payers also remains limited. Recent KFF analysis also found most large employer firms do not cover GLP-1 drugs for weight loss, coverage in ACA Marketplace plans remains limited, and coverage in Medicare is prohibited.

Thirteen States Covered GLP-1s for Obesity Treatment as of August 2024

How have Medicaid prescriptions and gross spending on GLP-1s changed in recent years?

The number of Medicaid prescriptions and gross spending on GLP-1s have increased rapidly in recent years, with both nearly doubling from 2022 to 2023. Overall, from 2019 to 2023, the number of GLP-1 prescriptions increased by more than 400%, while gross spending increased by over 500%. Spending per prescription before rebates reached more than $900 per prescription in 2023. Those prices and spending numbers do not account for rebates, and states are likely receiving substantial rebates on these brand drugs. While rebate data for specific drugs is not publicly available, Medicaid and CHIP Payment and Access Commission (MACPAC) analysis of FY 2020 data found statutory rebates accounted for 61.6% of gross Medicaid spending on brand drugs. Also, amid growing criticism of the cost of their drugs, Novo Nordisk, the company that creates Ozempic and Wegovy, has said that rebates and other fees (across all payers) account for about 40% of the cost of the two drugs. The GLP-1s in this analysis still account for relatively small shares of the total number of Medicaid prescriptions and spending before rebates, though the shares are growing. By 2023, these drugs accounted for 0.5% of all Medicaid prescriptions (up from 0.01% in 2019) and 3.7% of all gross Medicaid spending (up from 0.9% in 2019).

Medicaid Prescriptions and Gross Spending on GLP-1s has Increased Rapidly in Recent Years

Specifically, increased utilization of Ozempic, Wegovy, and Mounjaro have contributed substantially to recent growth. Prescriptions and spending on Ozempic, approved to help control blood sugar levels for adults with type 2 diabetes in 2017 (Table 1), have grown considerably from 2019 to 2023, nearly doubling every year since 2019. Looking from 2022 to 2023, the latest year of data available, Wegovy (first approved in 2021) and Mounjaro (approved in 2022) also saw substantial growth, with prescriptions and gross spending for both drugs increasing twelvefold or more. This analysis includes GLP-1 formulations approved for obesity treatment as well as the same formulations approved for type 2 diabetes (for more information on how GLP-1s are identified in this analysis, see Methods). From Medicaid data publicly available, there is no way yet to disentangle how much of the growing use of GLP-1s is related to treatment for diabetes versus obesity, or a combination of both. In addition, the popularity and increased demand for GLP-1s has led to drug shortages, sometimes causing people to switch products or ration doses or sometimes leaving individuals without access to needed prescriptions. This may have implications for drug trends, though the FDA recently reported that GLP-1 supplies are beginning to stabilize.

U.S. FDA Approvals of Select GLP-1s

How may the coverage landscape of GLP-1s for obesity treatment change?

Many state Medicaid programs are considering covering obesity drugs in the future but are concerned about the cost implications. KFF’s annual budget survey found that, among those states that do not currently cover obesity drugs, half reported they were considering adding coverage, with a few states reporting plans to add or expand coverage in FY 2025 or later. When asked about the key factors contributing to their obesity medication coverage decision, almost two-thirds of responding states mentioned cost, though states are also weighing a number of other factors including the need for legislative action, adherence concerns, clinical criteria development, and potential side effects. Conversely, 4 in 10 states noted that positive health outcomes and longer-term savings on chronic diseases associated with obesity were key factors in their decision to cover or consider covering in the future along with increasing enrollee access and health equity, recommendations from providers, and ability to negotiate supplemental rebate agreements. States are likely considering various cost containment strategies for these drugs and may even be re-evaluating their broader approach to obesity treatment, including the use of obesity medications along with other treatments such as nutritional counseling or behavioral therapy. Obesity is caused by a multitude of complex factors, and uptake of GLP-1s could improve health but would not address all of the underlying contributors to obesity.

Figure 3 is titled "State Medicaid Programs Reported Cost Was a Major Factor in Obesity Drug Coverage Decisions" and divides different parts of a rectangle into Reasons for Covering and Reasons for Not Covering.

Methods

Number of Prescriptions and Gross Spending Data: This analysis uses 2019 through 2023 State Drug Utilization Data (SDUD) (downloaded in October 2024). The SDUD is publicly available data provided as part of the Medicaid Drug Rebate Program (MDRP), and provides information on the number of prescriptions, Medicaid spending before rebates, and cost-sharing for rebate-eligible Medicaid outpatient drugs by NDC, quarter, managed care or fee-for-service, and state. It also provides this data summarized for the whole country. The data do not include information on the number of days supplied in each prescription. CMS has suppressed SDUD cells with fewer than 11 prescriptions, citing the Federal Privacy Act and the HIPAA Privacy Rule. This analysis used the national totals data because less data is suppressed at the national versus state level.

Identifying GLP-1s: GLP-1 agonists included in the analysis were approved for treatment of obesity, Saxenda (liraglutide), Wegovy (semaglutide), Zepbound (tirzepatide) and corresponding formulations that may potentially be used off-label for treatment of obesity, Mounjaro (tirzepatide), Ozempic (semaglutide), Rybelsus (semaglutide), Victoza (liraglutide), mirroring another recent KFF analysis. Other GLP-1 agonists with active ingredients only approved for treatment of diabetes that have less potential for off-label weight loss use (such as Bydureon BCise, Trulicity) were not included.

Limitations: There are a few limitations to the estimates of Medicaid prescriptions and gross spending found in this analysis, including:

  • This analysis examines the number of Medicaid prescriptions in the data and does not adjust for days supplied by each prescription.
  • Gross spending and spending per prescription numbers do not account for rebates.
  • The SDUD are updated quarterly; a new quarter of data is typically released, and the prior five years of data are also updated. This means utilization and gross spending totals can vary depending on when the data is downloaded, and totals may not match other outside sources or prior KFF analysis for this reason.
  1. Drugs that may be excluded from coverage under the MDRP include drugs used for: a) anorexia, weight loss, or weight gain, b) promoting fertility, c) cosmetic purposes or hair growth, d) symptomatic relief of cough and colds, e) prescription vitamins and mineral products except prenatal vitamins and fluoride preparations , f) nonprescription drugs, g) a manufacturer’s covered outpatient drug in which tests and monitoring services have to be purchased from that manufacturer, h) sexual or erectile dysfunction unless used to treat a condition. For more information see, 42 U.S.C. § 1396r-8. ↩︎

Understanding Racial and Ethnic Identity in Federal Data and Impacts for Health Disparities

Published: Nov 1, 2024

Introduction

How we ask for, analyze, and report information on race and ethnicity affects our ability to understand the racial and ethnic composition of our nation’s population and our ability to identify and address racial disparities in health and health care. The accuracy and precision of such data have important implications for identifying needs and directing resources and efforts to address those needs. Race, ethnicity, and national origin are distinct concepts that are social constructs, and how they have been defined, identified, and/or categorized have evolved over time. This brief provides an overview of how the concepts of race, ethnicity, and nationality have been defined and measured by the federal government through the U.S. Census Bureau and the Office of Management and Budget (OMB) over time and the implications for health disparities. We acknowledge that this brief does not cover all the nuances and complexities of the topic of racial and ethnic identity and that there is variation in how people think, talk, and relate to race, ethnicity, and national identity.

What do Race, Ethnicity, and National Origin Represent?

The concepts of race, ethnicity, and national origin and their fluidity are reflective of these identities being social constructs. While different, the two concepts of race and ethnicity are connected. Race is defined as a social political category primarily based on physical characteristics such as skin color, and ethnicity is a social category primarily defined by culture, language, and history. National origin is defined by the country or region that an individual or their ancestors originate from. In a 2024 update, federal standards for collecting and reporting racial and ethnic data combined previously separate questions about race and Hispanic ethnicity into a single question, and a new category was added for Middle Eastern or North African (MENA) people. The updated federal standards utilize seven racial and ethnic categories that are identified with the following terms (see Appendix for more details):

  • American Indian or Alaska Native (AIAN)
  • Asian
  • Black or African American
  • Hispanic or Latino
  • Middle Eastern or North African (MENA)
  • Native Hawaiian or Pacific Islander (NHPI)
  • White

There are distinctions in the meanings of and community preferences for different terms, such as Black and African American and Hispanic, Latino, or Latinx. Polling data over time show that half of those who trace their roots to Spanish-speaking Latin America and Spain have consistently said they have no preference for Hispanic or Latino, but that when asked to choose one term over another, Hispanic has been preferred to Latino. Surveys further show a preference for country-of-origin labels (such as Mexican, Cuban, or Ecuadorian) versus broader pan-ethnic terms. A 2023 survey of U.S. Hispanic adults found that 47% of U.S. adults who self-identify as Hispanic have heard of the term Latinx, and just 4% say they use it to describe themselves. A 2021 Gallup Poll similarly found that most people favor the use of the term Hispanic and few (4%) prefer Latinx. Polling data also show that most Black Americans do not have a preference between Black and African American when asked which term they would rather people use to describe their racial group.

A large and growing share of people identify with more than one of the previous federal racial and ethnic categories (which do not reflect the 2024 changes to the standards). KFF analysis of 2023 American Community Survey (ACS) data finds that about eight in ten (81%) AIAN and two thirds (66%) of NHPI people identify with more than one racial and/or ethnic group. About one in five Asian (20%), Black (18%), and White (21%) people also identify with more than one racial and/or ethnic group (Figure 1). Under previous standards which had separate questions for Hispanic ethnicity and race, people of Hispanic ethnicity may be of any race.

Majorities of AIAN and NHPI People Identify With More than One Race or Ethnicity

Racial identity is important to how people think about themselves, particularly for Black and Hispanic people. In a recent KFF survey, a majority of Black (83%) and Hispanic (70%) people said that their racial identity is very or extremely important to how they think about themselves. About half of Asian (51%) people say the same. Data were unavailable for other racial and ethnic groups (Figure 2).

A Majority of Black, Hispanic, and Asian Adults Say Their Racial Identity is Important to Them

How Have Measures of Race, Ethnicity, and National Origin Evolved Over Time?

Since its inception in 1790, the U.S. census has collected information on race and ethnicity that has informed policy, the allocation of resources, and scientific research on different groups within the country. The race and ethnicity data collected by the census is also used to evaluate the effectiveness of government programs and policies as well as to measure and ensure fairness, equity, and compliance with anti-discrimination laws and policies. In 1977, OMB established federal standards for race and ethnicity data through Statistical Policy Directive No. 15 to standardize how data are collected and reported at the federal level. The OMB standards guide not only the census but also other federal surveys, ensuring consistency across government data collection efforts. The census aligns its racial and ethnic categories with these standards, though it occasionally adjusts them to reflect evolving understandings of identity. The census recognizes that race is a social construct, stating that “The racial categories included in the census questionnaire generally reflect a social definition of race recognized in this country and not an attempt to define race biologically, anthropologically, or genetically. In addition, it is recognized that the categories of the race item include racial and national origin or sociocultural groups.”

How the census has collected and categorized information on race and ethnicity has evolved significantly over time, reflecting social and political shifts and the growing diversity of the U.S. population (Figure 3).

U.S. Census Collection of Racial and Ethnic Data Have Evolved Over Time
  • Between 1790 and the mid-20th century, race and ethnicity information was collected via enumerators who conducted an interview for each household. Enumerators identified individuals’ racial and ethnic identities through their observations based on criteria that included physical characteristics, social norms and principles, national origin, and Tribal affiliation. Between 1790 and 1860, the census collected information on White, Black (enslaved and free), and Other Free Persons.1 
  • Additional categories were added to the census in the 1800s, which were motivated by slavery and race science and maintaining rights and privileges for White people. The 1840 census introduced a new category, free colored people (including Black and mixed-race Black people). In the mid to late 1800s, mixed-race categories were added — “mulatto, quadroon, and octoroon”. The definitions of these categories evolved over time, but they were based on perceived shares of Black ancestry and are no longer used. American Indian people who renounced Tribal rule, exercised the rights of U.S. citizens, and paid taxes were counted in the census for the first time in 1860. Prior to that, the Constitution excluded American Indian people who lived on reservations, lived on unsettled land, or were not taxed from being enumerated. By the late 1800s, the census began collecting national origin information, coinciding with the entry of Chinese migrant workers.
  • Amid the rise of Jim Crow laws, the 1930 census dropped mixed-race categories and focused on the collection of single race data. Up until 1970, census enumerators classified people of mixed-race heritage based on specific rules: those with White ancestry and another racial group were classified as “non-White,” and people with two “non-White” ancestries were classified by the father’s race. If a person was Black or AIAN, their racial identity was instead based on blood quantum rules. Blood quantum measures the percentage of American Indian or Alaska Native ancestry or blood that an individual has and is used to determine Tribal affiliation. People who were both Black and White were categorized as Black under the one-drop rule, which meant that a person with any percentage of Black ancestry or blood would be counted as Black.
  • Also during this period, more disaggregated Asian national origin data were collected, and Mexican national origin data were collected for the first time. Before 1930, Mexican Americans were classified as White. There was an organized movement to remove the Mexican category and reclassify Mexican people as White. Mexican people were reclassified as White in the 1940 census until 1970 when the census added the Hispanic/Latin origin category to a version of the questionnaire that was sent to a small share of the U.S. population.
  • In the mid-20th century, the census shifted to allow respondents to self-identify their own race and/or ethnicity. Respondents were instructed to select the race that they most closely identified with from the single-race categories available or to use the father’s race if they were uncertain. Further, the addition of two new states in 1959, Alaska and Hawaii, prompted the addition of new categories to the census in 1960; Eskimo, Aleut, Hawaiian, and part-Hawaiian.
  • In 1980, the census added a separate question on Hispanic ethnicity, following lobbying efforts from Hispanic advocacy groups in the 1970s in response to undercounting of the Hispanic population in the census. The Asian Pacific Islander (API) category was also added at this time in response to lobbying by Asian American legislators and advocacy groups, who similarly found that Asian American and Pacific Islander people were being undercounted. The API indicator included nine detailed Asian and Pacific Islander origin categories.
  • In 1997, the OMB revised its race and ethnicity standards to allow individuals to select more than one racial category, reflecting a growing recognition of multiracial identities. This revision aimed to improve data accuracy and better capture the diversity of the U.S. population. Other open-ended questions on ancestry or ethnic origin were added that led to broader ethnic identification among American Indian people with a large share of the population claiming some Indian ancestry even if they didn’t identify racially as American Indian. This may have reflected increased American Indian pride movements that prompted people with multiracial American Indian heritage to identify with their American Indian ancestry.
  • The second major change that impacted people with mixed-race heritage occurred in 2000, when the census allowed people to select more than one racial category. This change was driven by the multiracial movement of the 1980s and 1990s. In 2000, the census combined the American Indian and Alaska Native categories to form the AIAN category to capture original peoples with origins in North, Central, and/or South America. It also asked respondents to provide the names of their enrolled or principal Tribes. Additionally, it began collecting information separately on NHPI people, which it defined as people having origins in any of the original peoples of Hawaii, Guam, Samoa, or other Pacific Islands.
  • The 2020 census allowed people to include detailed information about their race and/or ethnicity in addition to marking multiple race categories. The census now allows respondents to provide write-in responses describing their race and ethnicity, with clearer instructions and examples based on the largest population groups for each category. The multiracial population grew significantly between 2010 and 2020, with the U.S. Census Bureau indicating that changes in the design, data processing, and coding of the race and ethnicity questions over this time period (including the write-in responses) contributed to this growth, highlighting the impact of these decisions. This change also led to more people of MENA heritage providing detailed information about their ancestry, whereas before they were aggregated into the White category.
  • In 2024, OMB released revised Standards for Maintaining, Collecting, and Presenting Federal Data on Race and Ethnicity to better reflect the growing diversity of the U.S. population. The revisions include using a single combined question for race and ethnicity, adding MENA as a minimum category, clarifying instructions for individuals to select multiple racial and ethnic categories that represent their identity, and requiring collection of more detail beyond the minimum categories. In addition, the standards require that data tabulation procedures result in the production of as much information on race and/or ethnicity as possible, including data for people reporting multiple racial and/or ethnic categories. These changes will impact how race and ethnicity data are collected in the census, as the U.S. Census Bureau has to adhere to the OMB standards on race and ethnicity.

While the census and OMB standards have been the standard for measuring race and ethnicity in the U.S. government at the federal level, states, localities, and other organizations often differ in their measurement of racial and ethnic data. For example, states vary in the number of categories they use to collect race and ethnicity data, as well as how these variables are named and combined. In Oregon, as part of an effort to eliminate health inequities, Oregon’s Health Authority has taken steps to accurately and expansively report demographic data. This includes collecting detailed and more granular race, ethnicity, language, and disability data. Oregon collects data for 42 race and ethnicity groups, answers are self-reported, and respondents are given the opportunity to select more than one race and/or ethnicity. Some states have narrower race and ethnicity categories, combining groups such as Asian and Native Hawaiian or Pacific Islanders into one group, API.

How Do Measures of Race, Ethnicity, and National Origin Impact Policies and Health Disparities?

How race, ethnicity, and nationality have been defined and measured has important implications for health disparities. Historically, these measures affected who can access health care, social services, education, and employment opportunities and have reinforced racial misinformation that limit access to resources for marginalized groups. Narrow and inconsistent race and ethnicity categories have obscured inequities and made it more difficult to meet the diverse needs of different populations. Conversely, data on race and ethnicity have also been used to address disparities by informing policies and interventions and to ensure compliance with antidiscrimination laws.

There are historic examples of racial and ethnic data being used in ways that have worsened and perpetuated racism and disparities. For example, in 1840, an “insane or idiot” category was added to the census to identify the number of people with mental disabilities in the country. However, the census enumerators disproportionately overcounted free colored people as “insane” to support the inaccurate idea that “freedom drove Black people mad.” Advocates of slavery used the 1840 census data to justify that slavery was beneficial for the health and well-being of Black people. In 1850, scientists petitioned the addition of a new racial category, “Mulatto” (people with mixed Black ancestry),  to study the health of multiracial enslaved people. Census data from this period contributed greatly to scientific racism. Scientists used this data to suggest people of color were inferior to White people, test theories of polygenism, and codify racial hierarchies. As the multiracial population grew, so did ideologies surrounding the rules of hypodescent, under which multiracial individuals are assigned the race of the parent from the marginalized racial group. This included the one-drop rule, which required that anyone with a discernible trace of African ancestry be considered Black. This concept ensured that the children of enslaved Black people and their White enslavers would remain slaves. Blood quantum categorization eventually led to the codification of the one-drop rule in some states during the Jim Crow era as a means of supporting segregation. Similarly, the census began collecting information on American Indian blood quantum in 1930. Blood quantum was not only used to determine Tribal membership but was also used to study any perceived biological and intellectual differences between American Indian and White people.

In addition, race has historically and continues to play a role in medical teaching and clinical decision making within health care. Historically, the medical and scientific community used race to explain differences in disease prevalence and outcomes, contributing to misperceptions about biological differences by race that were used to justify mistreatment. Within U.S. medical curricula, the concept of race led to since disproven theories of biological inferiority of people of color and White supremacy, which fueled an array of atrocities in medicine including the forced sterilization efforts targeting Black and Native American women, the use of Henrietta Lacks’ cells for scientific research without consent, and the infamous U.S. Public Health Service Untreated Syphilis Study at Tuskegee, among others. Today, research suggests that provider and institutional bias and discrimination are drivers of disparities and health. Race also continues to be used as a factor in some clinical algorithms, although there is growing movement to eliminate the use of race and to ensure that disparities are not perpetuated amid the growing use of artificial intelligence and algorithms to guide clinical decision making.

Conversely, racial and ethnic measures have also been used to mitigate inequities in policies, employment, health care, and other sectors. For example, the Civil Rights Movement in the mid-20th century prompted the standardization of racial and ethnic classification as well as documentation of trends in racial and ethnic discrimination. This resulted in the establishment of the OMB Statistical Policy Directive No. 15 in 1977 that has since standardized the collection of race and ethnicity data at the federal level. The collection of standardized data facilitates the ability for policymakers and institutions to identify and address areas of inequality. For instance, racial and ethnic data can inform resource allocation, ensuring communities facing systemic disadvantages receive essential services, such as health care, education, and social programs. Additionally, it can help track and mitigate racial bias and discriminatory practices in health care, employment, housing, and other social and economic domains. These data also allow for the evaluation of the effectiveness of interventions designed to reduce disparities. For example, public health programs can measure the impact of vaccinations, screenings, or outreach efforts in marginalized communities, using racial and ethnic data to refine strategies and ensure more equitable access to care.

Availability of racial and ethnic data also has impacts on efforts to address health disparities. Missing or inconsistent data on race, ethnicity, and nationality can hinder effective resource allocation and policy decision-making, particularly in efforts to address health disparities. AIAN people were excluded in early versions of the census, beginning a trend of exclusion from national data inquiry that continues to the present day. This exclusion from data and analysis has contributed to limiting the visibility and understanding of challenges faced by AIAN people and other smaller racial and ethnic groups, including NHPI people. The negative impacts of missing or incomplete data were evidenced during the COVID-19 pandemic, when inconsistencies and limitations in how states reported their data limited the ability to understand racial and ethnic disparities in COVID-19 health impacts as well as take-up of COVID-19 vaccinations. Arab Americans and people with ancestry in the Middle East or North Africa have been invisible in key datasets, resulting in a limited understanding of their health outcomes, experiences accessing health care, and engagement with the health care system. Increasing the availability of disaggregated racial and ethnic data facilitates a greater understanding of disparities in health and health care and can help focus efforts to address them. For example, while aggregate data on Asian people suggest that they fare the same or better as compared to White people across most measures of health and health care, they mask underlying disparities among smaller subgroups within the Asian community. Having more disaggregated data allows for a more nuanced understanding of people’s experiences and can facilitate focused efforts to address disparities as well as to measure impacts of interventions to address them.

As the U.S. becomes more diverse, it will be increasingly important to consider how to identify people’s identities, particularly among multiracial people. The census projects that people of color will account for over half of the population by 2050 with the largest growth occurring among people who identify as Asian or Hispanic. This shift underscores the importance of refining racial and ethnic categories to capture the complexity of modern identities. Continued adaptation of data collection and reporting methods will be important for reflecting experiences among multiracial people.

Continued efforts to further disaggregate racial and ethnic data may be important for guiding efforts to address health and health disparities. Significant data gaps persist for smaller groups, including AIAN and NHPI people, with very limited information available for subgroups of these populations. Moreover, Asian and Hispanic people are often treated as monolithic in policy discussions, but the diversity in experiences among these groups is vast, encompassing differences in national origin, language, immigration status, and socioeconomic factors that all influence health. Disaggregating data by subgroup can allow for more nuanced understanding of the challenges faced by specific groups and facilitate tailored efforts to address them. For example, the health care experiences of Asian immigrants vary in meaningful ways due to the intersections of race and ethnicity, national origin, income, and other factors that may impact access to health care services. Moreover, data are often key for justifying allocation of resources toward specific communities or groups.

Increased recognition of the intersectional nature of people’s identities and other factors that may affect their health and health care experiences may also have important implications for efforts to address disparities. For example, the combination of race, ethnicity, and gender, highlights disproportionate discrimination for certain groups. Large federal surveys collect demographic and social data, including race and/or ethnicity, gender, educational attainment, and income that can allow researchers to examine how intersectional social and economic factors shape people’s health and experiences. However, in some cases, data are limited to examine experiences by multiple factors. Beyond an individual’s racial or ethnic identity, other factors that are less routinely collected in surveys, such as self-perceived skin color, can also influence their experiences. Socially-assigned race—that is the race that others perceive someone to be—may also be a factor. For example, studies have found that Hispanic or Latino individuals who are socially perceived as White report better health outcomes than those who are perceived as Hispanic or Latino. As efforts to address health disparities continue and evolve, it will be important to consider how these other factors influence people’s experiences and outcomes.

Appendix: Examples of Race and/or Ethnicity Questions Consistent with Revised OMB Standards

Representation of a questionnaire with prompt "What is your race and/or ethnicity? Select all that apply." The options are American Indian or Alaska Native, Asian, Black or African American, Hispanic or Latino, Middle Eastern or North African, Native Hawaiian or Pacific Islander, and White.

Source: Office of Management and Budget, Revisions to OMB’s Statistical Policy Directive No. 15: Standards for Maintaining, Collecting, and Presenting Federal Data on Race and Ethnicity

Representation of a questionnaire with prompt "What is your race and/or ethnicity? Select all that apply and ener additional details in the spaces below." The options are American Indian or Alaska Native, Asian, Black or African American, Hispanic or Latino, Middle Eastern or North African, Native Hawaiian or Pacific Islander, and White. Each option has a white box to provide further context.

Source: Office of Management and Budget, Revisions to OMB’s Statistical Policy Directive No. 15: Standards for Maintaining, Collecting, and Presenting Federal Data on Race and Ethnicity

  1. Between 1790 and 1840 only the heads of free households appeared in early census records, enslaved people were not recorded by name, age, sex, or origin. They only included additional demographic data on White people. ↩︎

PEPFAR: Exploring Co-Financing as a Tool for Domestic Resource Mobilization

Author: Jennifer Kates
Published: Nov 1, 2024

Issue Brief

There is growing pressure on PEPFAR, the U.S. global HIV program, to increase its planning for sustainability, including through domestic resource mobilization and, ultimately, transitioning financing at least in part to recipient countries.1  While this is connected to a broader push in global health and development, driven by a constrained financing environment and desire to promote more country ownership of programs and services2 , there are specific questions facing PEPFAR’s future. A National Academy report from 2017, for example, recommended that PEPFAR look toward phasing down its spending and supporting countries in their transition from bilateral aid to domestic financing for HIV. At a Senate hearing last year, PEPFAR was asked how it was working to increase domestic resources and under what conditions would it need less resources to accomplish its goals. Recent challenges in securing a five-year reauthorization of the program have only served to heighten the focus on sustainability and domestic resource mobilization.  How PEPFAR does this, however, remains an ongoing question.

One potential tool is “co-financing” (sometimes referred to as “cost-sharing” or “co-investment”) – that is, to require country recipients of PEPFAR funding to contribute resources to the HIV response. Co-financing is used for a variety of reasons, including to help share or spread costs and to promote ownership and sustainability in programs.3   Indeed, several global health and development institutions employ some kind of co-financing arrangement, as do some U.S. government programs.  While PEPFAR, and most U.S. global health and development programs, are bound by requirements under the Foreign Assistance Act to ensure some level of cost-sharing by countries,4  some stakeholders have specifically recommended that PEPFAR adopt a policy either to mobilize additional resources or to facilitate reduced U.S. funding.5 

This policy brief identifies options and issues PEPFAR could consider if it moves in the direction of a new co-financing policy, based on the experiences of other global health and development institutions. It first examines current U.S. law regarding co-financing and PEPFAR’s prior experience with domestic resource mobilization. It then assesses the co-financing policies6  of six other institutions to draw out questions and issues for PEPFAR. The six institutions examined were: Gavi, the Vaccine Alliance (Gavi); the Global Environment Facility (GEF); the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund); the Green Climate Fund (GCF); the Millennium Challenge Corporation (MCC) and the Pandemic Fund (PF).

Current U.S. Law and PEPFAR’s Experience

U.S. Law

The Foreign Assistance Act (FAA)7 , which governs U.S. foreign assistance and programs including PEPFAR and other global health efforts, has long had a co-financing requirement (which it refers to as “cost-sharing”). Specifically, Section 110 of the FAA, as amended, states that:

“No assistance shall be furnished by the United States Government to a country under Sections 103 through 106 of this Act until the country provides assurance to the President, and the President is satisfied, that such country will provide at least 25 per centum of the costs of the entire program, project, or activity with respect to which such assistance is to be furnished, except that such costs borne by such country may be provided on an “in-kind” basis.”8 

The requirement applies to bilateral development and global health assistance that is obligated to a host country (but not to grants, cooperative agreements, or contracts with public international organizations, non-governmental organizations, or other implementing partners unless obligated through a bilateral agreement with the host country.)  Sources of cost-sharing are expected to come from host country budgets, although in some cases, they may come from other country resources. In-kind contributions (e.g., buildings, materials, personnel, as well as policy actions or institutional changes that further project goals) are also allowable. There is also an option to waive the cost-sharing requirement (under Section 124(d) of the FAA) on a case-by-case basis for “relatively least developed countries”, defined as countries on the DAC list of aid recipients categorized as “least developed countries” or “other low income countries” or those on the World Bank’s “heavily indebted poor countries” (HIPC) list.  This policy, while assuring some level of cost-sharing by countries, does not require progressive or additional country financing over time.

PEPFAR’s Experience

While created in 2003 as an emergency program, the importance of building sustainable capacity  in PEPFAR countries was recognized from the onset, including in PEPFAR’s authorizing legislation and first strategy. When the program was reauthorized five years later, in 2008, Congress placed an even greater emphasis on sustainability and instructed PEPFAR to develop new compacts or framework agreements with countries to promote sustainability that, among other things, included “cost sharing assurances” that met the requirements of FAA Section 110 (essentially reiterating the current law). 9   PEPFAR developed “Partnership Frameworks” guidance and, in addition to the cost-sharing requirement, encouraged countries to increase domestic resources where possible. For example, the guidance stated: “For purposes of Partnership Frameworks, promoting sustainability means supporting the partner government in growing its capacity to lead, manage, and ultimately finance its health system with indigenous resources (including its civil society sector), rather than external resources, to the greatest extent possible.” In addition, it called for the development of a timeline of increasing partner government financial commitments and criteria for tracking such support. Ultimately, PEPFAR developed Partnership Frameworks with 22 countries and regions, but these were time limited arrangements that ended after a five-year period. In addition, an evaluation identified several challenges with realizing increased domestic resources, including: vague indicators that made monitoring and measurement difficult; the absence of financing commitments in some agreements or inclusion of non-domestic sources as commitments; the lack of evidence for increased domestic investment; and economic hardship that made it difficult for some countries to contribute resources.

Beyond Partnership Frameworks, PEPFAR has, at other times, sought to emphasize the importance of and/or mobilize additional domestic resources from countries. For example:

  • In its 2012 Blueprint for Creating an AIDS Free Generation, PEPFAR stated that it would work to “implement incentives for annual progressive increases in domestic cofinancing that complement strategic investments by donors”.
  • In 2013, PEPFAR guidance included the need for countries to increase and report on the use of their own resources for the HIV response, and categorized countries by their economic capacity, including countries that could “co-finance” more of their response. Also at that time, PEPFAR instituted Sustainability Plans as a way to work with countries to, among other things, increasingly finance the national HIV response.
  • In 2019, PEPFAR introduced “Minimum Program Requirements” (MPRs), one of which was the need for countries to provide evidence of increased resource commitments by host governments annually.
  • Currently, PEPFAR is working to develop “Sustainability Roadmaps” with countries that will include the need to increase domestic financing of the HIV response.

Beyond the cost-sharing requirement that already exists under the FAA, however, PEPFAR has not instituted a policy designed to mobilize additional domestic resources over time from countries, as some have called for, and there is limited information available on the status of its prior efforts.

Box 1: Co-Financing Policy Considerations

  1. Linking co-financing to mission and objectives
  2. Scaling co-financing to country income/fiscal health
  3. What “counts” as a co-financing source
  4. Specifying co-financing amounts/shares
  5. Specifying progressive co-financing
  6. Allowing for exceptions/waivers
  7. Identifying clear measurement, monitoring, and reporting criteria
  8. Addressing non-compliance
  9. Piloting or phasing-in a new policy
  10. Coordination with other donors

Considerations for PEPFAR

Should PEPFAR choose to institute such a requirement, analysis of the co-financing policies of six other institutions raises questions and issues for PEPFAR to consider, including (see Box and Appendix):

  1. Linking co-financing to mission and objectives. All six institutions examined link co-financing to their organizational missions, priorities, and/or project objectives. For example, Gavi’s co-financing requirement is specific to the purchase of vaccines; the GEF policy is intended to support implementation of a GEF-financed project or program and achievement of its objectives; and the MCC requires contributions from countries toward meeting MCC objectives. The Global Fund has a mix: it ties some co-financing to Global Fund programs, but also to broader, health system financing.  In PEPFAR’s case, co-financing could be tied to the national HIV program, as it was in its prior Minimum Program Requirement. This approach would support Congressional intent to combat HIV, and sustainability of the HIV response specifically. Additionally, PEPFAR could consider tying co-financing to a specific HIV-related service or activity only (as Gavi does). On the other hand, a broader approach, similar to the Global Fund’s tying co-financing to the health system, may yield wider health benefits (although not necessarily for HIV).
  2. Scaling co-financing to country income/fiscal health. Three institutions – Gavi, the Global Fund, and the MCC – scale co-financing amounts or policies to country income classifications (requiring greater contributions from countries with higher incomes). Scaling a new co-financing policy this way would protect PEPFAR recipient countries with less fiscal capacity and recognize the greater capacity of countries with stronger economies. However, since such an approach may not capture the full fiscal health of a country or burden on individuals and households, PEPFAR could also consider using additional measures, such as debt burden, share of household out-of-pocket expenditures on health, and/or share of domestic revenues spent on health, to assess country fiscal capacity.
  3. What “counts” as a co-financing source. The six institutions examined vary in the sources and types of resources they count towards fulfilling co-financing requirements. While all six include domestic resources, only the Global Fund limits allowable co-financing to domestic revenues; in its case, these could be domestic public resources (government revenues, government borrowings, social health insurance, and debt relief proceeds) and/or domestic private resources (contributions from domestic corporations and philanthropies). The others allow multiple sources to fulfill co-financing requirements, including, in some cases, external donor support. Two institutions – the GEF and the MCC – explicitly include in-kind contributions as a source of co-financing. If PEPFAR pursues a new policy, assessing and identifying allowable sources would be important for setting clear expectations. Whether such sources are limited to domestic revenues only (as in the case of the Global Fund) or broader sources (as in the case of other institutions) may depend on PEPFAR’s goals (e.g., if it is interested in mobilizing additional domestic revenues specifically or in substituting for U.S. government resources more generally).
  4. Specifying co-financing amounts/shares. Few institutions examined include a specific co-financing amount. Exceptions are Gavi and the MCC (Gavi has specific price per dose requirements and the MCC has specific percentage requirements, each scaled in some way to country circumstances). The Global Fund, on the other hand, has a more general requirement to increase the amount invested over time and the GEF, GCF, and PF do not have any specifications for countries or projects, though the GEF does have overall co-financing targets at its full portfolio level. PEPFAR could consider specifying an amount or percentage of co-financing, which might be easier to measure and provide predictable projections of co-financing. Alternatively, it could consider a more general requirement to increase co-financing over time (akin to its earlier Minimum Program Requirement and the Global Fund’s policy), which may be easier to implement and allow for more flexibility for countries based on their unique circumstances, but not provide predictability and could be harder to measure.
  5. Specifying progressive co-financing. While all six institutions include the importance of “additionality” in their definitions (that co-financing brings additional resources to the project, mission, or health system) only two institutions – Gavi and the Global Fund – specifically require an increasing share of resources to be provided over time. Gavi’s policy is designed to have countries progressively co-finance their vaccines until they are fully funding vaccine procurement. The Global Fund requires countries to demonstrate progressive government expenditure on health and increasing co-financing of Global Fund supported programs. While not a requirement, the PF encourages countries to progressively commit to increasing co-financing over time. On the other hand, the MCC’s requirement is static, set at a specific percentage that does not change over time, and the GEF and GCF do not have any specific requirements for countries. If PEPFAR’s goal is to mobilize additional domestic resources it might consider setting a co-financing level above what a country does now or designing a progressive co-financing policy, along the lines of what Gavi has done (having countries increasingly finance their own programs over time).
  6. Allowing for exceptions/waivers. All but one institution (the GCF) includes an explicit provision regarding waivers of co-financing in exceptional circumstances, typically for fiscal or humanitarian crises. Including such a provision is intended to protect countries when they encounter unexpected or protracted difficulties or otherwise face challenging conditions. U.S. law already allows for this in its cost-sharing requirement, albeit only for certain countries. PEPFAR could consider expanding this to apply to any country it supports, if it were to institute a co-financing requirement.
  7. Identifying clear measurement, monitoring, and reporting criteria. How institutions measure, monitor, and report on co-financing contributions varies significantly and is generally more stringent if co-financing is required and there are repercussions for non-compliance (see below). For example, for Gavi, measurement and monitoring are based on the actual purchase of vaccine doses by countries. The MCC requires verifiable country records and may conduct on-site monitoring and verification. The Global Fund requires government letters of commitment and monitors commitments based on verified budget or other documentation. The PF, however, more generally states that co-financing will be documented in annual reports. Choosing clear measurement and monitoring, as well as reporting, criteria, will be important for the success and accountability of any new policy.
  8. Addressing non-compliance. While all six institutions require co-financing information to be submitted in applications, only three – Gavi, The Global Fund, and the MCC – state that they will take action for non-compliance, including the potential to lose financial support. The other three do not specify any consequences for non-compliance, although the GCF and PF say they score applications, in part, based on submission of co-financing information. Whether PEPFAR decides to include consequences for non-compliance will likely affect the strength of the policy but also could potentially risk adverse consequences on program outcomes (e.g., if non-compliance resulted in loss of funding that threatened vital services). To address this concern, PEPFAR could consider implementing “guardrails” that protect certain services (e.g., antiretroviral treatment) or populations (e.g., key and vulnerable populations) from loss of funding due to country co-financing non-compliance.
  9. Piloting or phasing-in a new policy. Because a co-financing policy would introduce a new element to PEPFAR’s relationships with countries, it could consider piloting the requirement in a subset of countries or for a subset of services and/or phasing it in over time. Gavi, for example, explored interim approaches to co-financing a few years before fully implementing its policy for all countries.10  As part of a pilot, PEPFAR could test whether incentivizing countries, at least in the short term (e.g., by offering additional matching funds for certain services or guaranteeing a certain amount of support for a period of time), might assist in a transition to co-financing, and help mobilize country resources over time.
  10. Coordination with other donors. Finally, if PEPFAR were to decide to institute a co-financing requirement, there is a risk that such a policy could overburden countries facing similar requirements from other institutions, and/or create mixed or cross-purpose incentives that could impact health outcomes. Coordinating across institutions would help to mitigate against these risks. In PEPFAR’s case, coordination with the Global Fund would be particularly important, given that both PEPFAR and the Global Fund support many of the same countries in their HIV response.

Whether PEPFAR ultimately decides to institute a new co-financing requirement remains to be seen, although Congress and other stakeholders are increasingly asking the program to identify ways in which it will promote sustainability and less reliance on U.S. government support over time. This analysis of other institutional co-financing policies offers a range of questions and issues for PEPFAR to consider should it move in this direction.

This work was supported in part by the Gates Foundation. KFF maintains full editorial control over all of its policy analysis, polling, and journalism activities.

Appendix

Appendix Table
 Gavi, the Vaccine Alliance (Gavi)Global Environment Facility (GEF)Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund)Green Climate Fund (GCF)Millenium Challenge Corporation (MCC)Pandemic Fund (PF)
Institutional Definition Share of total costs of vaccines borne by countries (not applied to Gavi funding for health systems/ immunisation strengthening).Financing that is additional to GEF project financing and supports implementation of a GEF-financed project or program and achievement of its objective(s) and excludes recurrent expenditures.Pooled domestic public and domestic private contributions that finance the health sector and national strategic plans supported by the Global Fund. Goal is to leverage additional domestic financing.Financial resources, whether public or private, in addition to the GCF proceeds to implement GCF funded activity or project.Contributions from countries toward meeting MCC objectives. These must be additional to government spending allocated towards Compact’s objectives.Co-financing is financial resources from Implementing Entities or other sources in addition to the PF grant.

Co-investment is financial resources and linked non-monetary policy commitments from countries in addition to PF grant.

Applies ToAll countries seeking support.All applicants.All countriesseeking support.All countries seeking support.All countries seeking Compact funding.All applicants.
Policy DetailsCountries required to share in cost of vaccine procurement for routine vaccination. Amount varies by country-income classification and transition status from Gavi eligibility. Countries divided into: initial self-financing ($0.20/dose); preparatory transition (first year at $0.20/dose; thereafter, price fraction increases by 15%/year); accelerated transition (price fraction increases by 15% in year 1, then linearly to 100%).Co-financing target set at overall GEF portfolio level, not individual program or project level, where no minimum amount specified. Overall portfolio target is co-financing to GEF project financing of at least 7:1 and 5:1 for portfolio in Upper-Middle Income Countries and High-Income Countries.Countries required to demonstrate progressive government expenditure on health (variable by share of domestic government spending on health and disease burden) and increasing co-financing of Global Fund supported programs. No specific amounts specified.

At least 15% of funding conditional on increases in co-financing (variable by country income classification). For LICs, additional domestic investments should be at least 50% allocation tied to co-financing; for MICs, it is 100%.

Co-financing information should be included in funding proposals and used as part of criteria for assessment. No minimum amount specified.Countries required to co-finance their Compacts. Specific co-financing amounts vary by country income classification and whether Compact is first, second, or concurrent as follows:  1st compact LIC (No minimum), 1st Compact LMIC (7.5%),

2nd Compact LIC (7.5%), 2nd Compact LMIC (15%);  Concurrent LIC or LMIC (required but no minimum specified).

Implementing entities encouraged to identify co-financing for projects.

Governments encouraged to commit to progressively increasing co-investments over time. Can be scaled to country income classification. Applications scored in part on this basis. No specific amounts specified. No minimum amount specified.

Source(s) of co-financingMust be non-Gavi funding.Can be from any source including funding from domestic governments, donors, civil society, and in-kind support.Domestic public resources can include government revenues, government borrowings, social health insurance, and debt relief proceeds including Debt2Health arrangements with the Global Fund.

Domestic private contributions include only those from domestic corporations and philanthropies.

No specific sources that must be complied with.Financial and in-kind country resources. Financial can include country government resources, as well as other financial instruments including cash, grants, loans, securities, guarantees. Cannot be USG (except DFC loan) or count toward other donor co-financing requirements.Co-financing sources: implementing entities, governmental donors, philanthropies, and the private sector.

 

Co-investment sources: Domestic government resources, buy down of interest rates, and repayments of loans.

Waivers/FlexibilityWaivers or adjustments can be made in exceptional circumstances (e.g., humanitarian or fiscal crises).Exceptions can be made in cases of emergency or unforeseen circumstances.Waivers can be made in exceptional circumstances (e.g., fiscal or humanitarian crises).Not specified, but GFC co-financing principles state that “Co-financing may not always be achievable or realistic”.Waivers of certain requirements on case by case basis, but requirement for lower middle income countries is statutory and cannot be waived.Exceptions can be made for countries in or at risk of debt distress.
Monitoring/ ComplianceRequirement fulfilled through actual co-purchasing of doses with Gavi and is condition for receiving support. A country in default will not be approved for new vaccine support, and funding disbursements for health system and immunization strengthening may be suspended.Secretariat collects data and information on expected and actual co-financing mobilized at the portfolio and recipient country level and reports annually.A letter outlining co-financing commitments and signed by the Ministry of Finance or other government authority is mandatory prior to grant approval. Compliance based on verified budget execution and budget allocation data provided by the country, through national expenditure assessments, or by audited financials. Failure to comply factored into subsequent allocations and Secretariat, at its discretion, may withhold proportional share of disbursements or reduce annual grant amounts.Accredited entities monitor and report on co-financing at the project level. Secretariat monitors and reports on overall co-financing at the funded activity and portfolio level based on the information provided by accredited entities.Must be verifiable by country records. Monitored by MCC and authorized agent. Additionality must be demonstrated. MCC may conduct on-site monitoring and verification. Audit reports must include co-financing information. If country not in compliance, MCC may withhold, reduce, suspend or terminate assistance.Documented in annual project reports.

 

Source documents:

Global Environment Facility

Global Fund

Green Climate Fund

MCC

Pandemic Fund

Endnotes

  1. In addition to financial, PEPFAR’s sustainability framework also includes political and programmatic domains. See, PEPFAR, FY 2024 Technical Considerations, available at: https://www.state.gov/wp-content/uploads/2023/07/FY-2024-PEPFAR-Technical-Considerations.pdf. ↩︎
  2. See, for example: The Future of Global Health Initiatives, 2023, The Lusaka Agenda: Conclusions of the Future of Global Health Initiatives Process, available at: https://d2nhv1us8wflpq.cloudfront.net/prod/uploads/2023/12/Lusaka-Agenda.pdf; Collins, Téa E et al., 2024, “Converging global health agendas and universal health coverage: financing whole-of-government action through UHC+”, The Lancet Global Health, Volume 11, Issue 12, e1978 – e1985, available at: https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(23)00489-8/fulltext. ↩︎
  3. See, for example: Millennium Challenge Corporation, Principles for Country Contributions, available at: https://www.mcc.gov/resources/doc/policy-country-contributions/#:~:text=Corporation%27s%20Accountable%20Entities.-,Principles%20for%20Country%20Contributions,-The%20following%20principles; Gavi Alliance, Co-Financing Policy, available at: https://www.gavi.org/sites/default/files/programmes-impact/Gavi-Co-financing-Policy.pdf; Global Fund, Sustainability, Transition, and Co-Financing Policy, available at: https://www.theglobalfund.org/media/14383/core_sustainability-transition-cofinancing_policy_en.pdf. ↩︎
  4. The Foreign Assistance Act of 1961, as amended, Section 110, available at: https://www.usaid.gov/sites/default/files/2022-05/faa.pdf#page=64. ↩︎
  5. Over M, Glassman, A, “Strengthening Incentives for a Sustainable Response to AIDS: A PEPFAR for the AIDS Transition”, in The White House and the World 2016, Center for Global Development. Available at: https://www.cgdev.org/sites/default/files/whw-pepfar.pdf; Meisburger T, Reassessing America’s $30 Billion Global AIDS Relief Program, Heritage Foundation, May 2023. Available at: https://www.heritage.org/sites/default/files/2023-05/BG3765.pdf.   ↩︎
  6. A recent analysis from the Center for Global Development also explored different agency co-financing models and assessed their relationship to spending patterns. See, Center for Global Development, 2024, Conditioned Domestic “Co-financing” Policies in Global Health: A Landscape Analysis, available at https://www.cgdev.org/sites/default/files/conditioned-domestic-co-financing-policies-global-health-landscape-analysis.pdf. ↩︎
  7. The Foreign Assistance Act of 1961, as amended, available at: https://www.usaid.gov/sites/default/files/2022-05/faa.pdf. ↩︎
  8. The Foreign Assistance Act of 1961, as amended, Section 110, available at: https://www.usaid.gov/sites/default/files/2022-05/faa.pdf#page=64. ↩︎
  9. While data on the value of cost-sharing by countries are not available, KFF analysis of PEPFAR obligations in FY 2022 (the most recent complete year available) finds that $216.6 million, or 3% of total PEPFAR obligations, went to governments. A 25% cost-sharing match would represent $54 million. ↩︎
  10. Dimitrios Gouglas, Klara Henderson, Jens Plahte, Christine Årdal, John-Arne Røttingen. 2014. Evaluation of the GAVI Alliance Co-financing Policy. Report commissioned by the GAVI Alliance. Norwegian Institute of Public Health, Oslo. ↩︎

A Look at Waiting Lists for Medicaid Home- and Community-Based Services from 2016 to 2024

Authors: Alice Burns, Abby Wolk, Molly O’Malley Watts, Maiss Mohamed, and Maria T. Peña
Published: Oct 31, 2024

Medicaid is the primary payer for long-term services and supports (LTSS) in the United States, and pays for more than two-thirds of the LTSS delivered in home- and community-based settings (HCBS). Most HCBS are optional for states to provide and are offered through “waivers,” which allow states to offer a wide range of benefits and to choose—and limit—the number of people who receive services. The only HCBS that states are required to cover is home health, but states may choose to cover personal care and other services, such as private duty nursing through the Medicaid state plan. States use HCBS waivers to offer expanded personal care benefits or to provide additional services such as adult day care, supported employment, and non-medical transportation. States also use waivers to provide specialized benefits that are specific to the population covered, such as providing supported employment only to people under age 65. KFF estimates that 4.5 million Medicaid enrollees use HCBS, and that the numbers of people using HCBS through the state plan are similar to the numbers using HCBS through waivers. A state’s ability to cap the number of people enrolled in HCBS waivers can result in waiting lists when the number of people seeking services exceeds the number of waiver slots available.

This data note provides new information about waiting lists from KFF’s most recent survey of state Medicaid HCBS programs, including a discussion of why waiting lists are an incomplete measure of unmet need and why they are not necessarily comparable across states or over time, despite KFF’s efforts to obtain as consistent data as possible (see Box 1). Key takeaways include:

  • The number of states that maintain waiting lists or interest lists for people who would like to receive HCBS has fluctuated little between 2016 and 2024.
  • In most years since 2016, there have been roughly 0.7 million people on waiting lists or interest lists, with a total of over 710,000 in 2024.
  • Most people on waiting lists or interest lists have intellectual or developmental disabilities and most live in states that do not screen any people for eligibility prior to adding them to waiting lists.
  • Most people on waiting lists or interest lists are eligible for personal care provided through states’ regular Medicaid programs or for services provided through specialized state plan HCBS benefits.
  • KFF also recently updated the waiting list indicators on State Health Facts, which show data by state and target population.

Waiting lists provide an indication of people who may need services they are not receiving, but they are an incomplete measure of unmet need because they don’t include people with unmet needs in states that do not cover the applicable services (and therefore, have no waiting list). Waiting lists reflect the populations a state chooses to serve, the services it decides to provide, the resources it commits, and the availability of workers to provide services. In addition, states’ approaches to managing waiting lists differ in how they prioritize and screen for eligibility, making comparisons across states difficult. States are only able to use waiting lists for optional services so the number of people on waiting lists can increase when states offer a new waiver or make new services available within existing waivers; in these cases, the number of people receiving services increases, but so does the number of people on a waiting list. Finally, although people may wait a long time to receive waiver services—40 months on average in 2024—most people are eligible for other types of HCBS while they wait.

Even though HCBS waiting lists are an imperfect measure of unmet need, there are no other alternative measures available. Many HCBS programs were enacted or expanded in response to the Olmstead decision, a court ruling that found the unjustified institutionalization of people with disabilities is illegal discrimination. As 2024 marked the 25th anniversary of Olmstead, waiting lists are sometimes described as contributing to the risk of unnecessary institutionalization for people with disabilities, and Democrats and Republicans alike proposed legislation in 2024 to address them. Starting in 2027, states will be required to report the number of people on waiting lists as required under a final rule on access to Medicaid services.

How did the number of states with waiting lists change between 2016 and 2024?

Between 2016 and 2024 the number of states with waiting lists has fluctuated between 37 and 41 and is currently at 40 states (Figure 1). While some Affordable Care Act (ACA) opponents have cited waiver waiting lists to argue that expanding Medicaid diverts funds from seniors and people with disabilities, research shows that ACA Medicaid expansion has led to gains in coverage for people with disabilities and chronic illnesses. Waiting lists for HCBS predate the ACA Medicaid expansion, which became effective in most states in 2014, and both expansion and non-expansion states have waiting lists. Waiver enrollment caps have existed since HCBS waiver authority was added to federal Medicaid law in the early 1980s.

Box 1: Changes to KFF’s Survey on Waiting Lists and Interest Lists, Starting in 2023

Starting in 2023, KFF asked states to report the total number of people who were on a “waiting list, referral list, interest list, or another term” for HCBS whereas surveys from 2022 and prior years only asked about waiting lists or referral lists. The change reflects states’ increasing use of terms other than “waiting list” to keep track of people who had expressed interest in HCBS but are not receiving services. KFF broadened the survey to increase the comparability of data across states and across years because states were transitioning to different terms.

Prior to 2023, some states used terms other than waiting lists to describe their lists and reported data in the KFF survey, but periodically a state would change its terminology and approach, resulting in what appeared a large fluctuation in the number of people on “waiting lists.” For example, in 2018, Louisiana had nearly 30,000 people on a waiting list for their intellectual or developmental disability waiver. The state implemented a new system to screen people for urgent HCBS needs. Those that met the criteria for urgent needs were placed immediately in services and people with less pressing needs were placed on a “registry” that replaced the older waiting list. By 2020, the waiting list was eliminated. KFF’s assessment was that a broader survey question would capture data more consistently, providing for more meaningful comparisons between states.

In 2024, there were slightly more people on interest lists (356,440) than on waiting lists (354,299). The use of the term “interest lists” has important ramifications for a recent rule on Medicaid access. Although the final rule would only require states to report people if they are on waiting lists, the preamble to the rule indicates CMS’ intent for states to report all types of lists.

A smaller change to KFF’s survey was to ask the states to report the number of people on the waiting list at the time the survey was completed rather than in the prior year. In the spring of 2023, KFF asked states to report the number of people on waiting lists in 2022, but also the number of people currently on the list. Starting in 2024, the survey only asks states to report the number of people currently on the list.

The Number of States with Waiting Lists or Interest Lists for Medicaid HCBS has Been Fairly Stable Since 2016 

There were more changes in waiting lists for specific types of waivers, however. Georgia, Kentucky, and West Virginia reported new lists for seniors/adults with physical disabilities (with a combined 2,683 people) and Alaska, Connecticut, South Dakota, and Washington reported new lists for people with intellectual or developmental disabilities (I/DD, with a combined 13,251 people on the lists). New Jersey newly reported a waiting list of nearly 2,700 people for its Community Care program, which serves people with I/DD and is part of the state’s larger 1115 waiver.

How did the number of people on waiting lists change between 2016 and 2024?

In most years between 2016 and 2024, roughly 0.7 million people have been on waiting lists or interest lists for HCBS (Figure 2). Between 2023 and 2024, total enrollment in waiting lists and interest lists increased by 2.6%. Overall, there was an increase in the number of people on waiting or interest lists in 19 states and a decrease in 14 states.

One factor that contributes to changes over time—especially the notable decline between 2018 and 2020—is that not all states screen for Medicaid eligibility prior to adding people to waiting lists and changes in this policy may result in changes in waiting list volumes. For example, between 2018 and 2020, the total number of people on waiting lists decreased by 155,000 or 19%. However, nearly half of that change came from Ohio’s implementation of a waiting list assessment of waiver eligibility, which reduced the size of the state’s waiting list by nearly 70,000 people. In 2024, most states (32) with waiting lists screen individuals for waiver eligibility among at least one waiver, but even among those states, 4 do not screen for all waivers. The 8 states that do not screen for eligibility among any waivers (Alaska, Illinois, Iowa, Oklahoma, Oregon, South Carolina, Texas, and Washington) account for over half of all people on waiting lists.

Over Half of People on HCBS Waiting Lists or Interest Lists Live in States That do not Screen People for Eligibility Prior to Adding Them to the List 

In all years since 2016, over half of people on HCBS waiting lists or interest lists lived in states that did not screen people on waiting lists for eligibility. One reason waiting lists provide an incomplete picture of need is that not all people on waiting lists will be eligible for services. Interviews about HCBS waiting lists found that when waiver services are provided on a first-come, first-served basis, people enrolled in waiting lists are in anticipation of future need. That study found that in some states, families would add their children to waiting lists for people with intellectual or developmental disabilities (I/DD) at a young age, assuming that by the time they reached the top of the waiting list, their children would have developed the immediate need for services. Many of those waivers offer comprehensive HCBS packages that include supported employment, supportive housing, or round-the-clock services. Among the eight states that do not screen people for eligibility on any lists, six have only waiting lists, one (Texas) has only interest lists, and one (Washington) uses both. (Illinois does not establish eligibility until selection but does a preliminary evaluation of eligibility prior to placing someone on the list.)

Between 2023 and 2024, several states made changes to their waiting list policies that resulted in notable changes in the number of people on a specific waiting list:

  • Illinois implemented a new law requiring school staff to discuss services for children with developmental disabilities in certain situations. The number of people on those two waiting lists increased from 14,444 to 15,905.
  • Iowa implemented a new process for assessing people’s need for services to move people with emergent needs higher on the waiting lists for waivers serving seniors/adults with physical disabilities and people with mental health needs. The number of people on the mental health waiting list increased from 802 to 1,128 and on the seniors/adults with physical disabilities waiting list increased from 9,684 to 10,508.
  • For its I/DD waiver serving children with Autism, Maryland added a screening call for applicants to ensure that children have an Individualized Family Service Plan or Individualized Education Program, and at least 15 hours each week of special education or related services prior to adding people to the waiting list. The change reduced the number of people on the waiting list from 6,431 to 5,280.

Who is on waiting lists for HCBS?

Most people on waiting lists have intellectual or developmental disabilities (I/DD), particularly in states that do not screen for waiver eligibility before placing someone on a waiting list. People on waiting lists for waivers serving people with I/DD (which include waivers specific to people who have Autism) comprise 89% of waiting lists in states that do not screen for waiver eligibility, compared with 49% in states that do determine waiver eligibility before placing someone on a waiting list (Figure 3). People with I/DD comprise almost three-quarters (73%) of the total waiver waiting list population. Seniors and adults with physical disabilities account for one-quarter (24%), while the remaining share (3%) includes children who are medically fragile or technology dependent, people with traumatic brain or spinal cord injuries, people with mental illness, and people with HIV/AIDS. People who are on HCBS waiting lists are generally not representative of the Medicaid population or the population that uses HCBS. Most people on waiting lists have I/DD, but KFF analysis shows that people with I/DD comprise fewer than half of the people served through 1915(c) waivers (the largest source of Medicaid HCBS spending).

Most People on Medicaid HCBS Waiting Lists or Interest Lists Have Intellectual or Developmental Disabilities

How long do people on HCBS waiting lists wait to access services and do they have access to HCBS while waiting?

In 2024, people on the waiting or interest lists accessed services after an average of 40 months (32 of 40 states responding), down from 45 months in 2021, but up from 36 months in 2023. People with I/DD waited the longest for services, 50 months on average. The average waiting period for other waiver populations ranged from 6 months for waivers targeting individuals with mental illness to 44 months for waivers that serve children. People with I/DD residing in states that do not screen for eligibility wait longer for services than people with I/DD residing in states that do screen for waiver eligibility (70 months versus 43 months, on average).

Most people on waiting or interest lists are eligible to receive other types of HCBS while they wait. Among the 710,000 people on lists for waiver services in 2024, living arrangements are unknown for more than 560,000. Among the people whose living arrangements are known, 98% (147,000) live in the community and 2% (3,300) live in institutional settings. While waiting for waiver services, people living in the community are likely to be eligible for other HCBS through Medicaid state plans. Of the over 4 million people who use HCBS, KFF estimates that roughly half use services provided through the Medicaid state plan, such as personal care to help with bathing or preparing meals, therapies to help people regain or acquire independent living skills, and assistive technology. States may not use waiting lists to restrict the number of people eligible to use such services and over 80% of people on HCBS waiting lists are eligible for personal care or other state plan services. They would not, however, have access to more specialized services such as supported employment or adult day care. People on waiting lists who receive state plan services may also have fewer hours of personal care than they would in a waiver program, or they may not have assistance with some of the activities they need help with such as bathing, dressing, preparing meals, or managing medication.

How are workforce shortages and changes in federal policy affecting HCBS waiting lists?

Although waiting lists may reflect states’ budget constraints, states also use waiting lists to manage shortages of HCBS workers, and with ongoing workforce shortages, it may be difficult to meaningfully reduce waiting lists. Rhode Island and West Virginia newly reported waiting lists because of workforce shortages. In Rhode Island, the waiting list captures people who are eligible for and enrolled in their 1115 waiver but are not receiving home care because of provider shortages. The state noted that provider shortages differ across communities, and that some people waiting for the authorized services might be living in institutions and waiting to transition to community living. West Virginia’s new waiting list for their mental health waiver reflects a lack of workers accepting new patients. Workforce shortages are not unique to Rhode Island and West Virginia, they were reported by all responding states in KFF’s 2023 survey of HCBS programs. It is unlikely that there will be major changes in states’ waiting lists for HCBS without corresponding changes in the availability of HCBS workers.

As states exhaust expanded federal funding for HCBS from the American Rescue Plan Act (ARPA), addressing waiting lists may become more difficult. Section 9817 of the ARPA provided states with an additional 10 percentage points of federal funding for their Medicaid HCBS expenditures between April 1, 2021, and March 31, 2022. States were required to reinvest this additional federal funding into Medicaid HCBS, resulting in an estimated $37 billion in new HCBS funding. As of December 31, 2023, the number one use of the ARPA funds—accounting for more than $26 billion of the planned $37 billion in new funding—was for workforce recruitment and retention. The second largest allocation (an additional $4 billion) was for workforce training. The end of extra workforce-oriented funding could exacerbate workforce challenges, potentially increasing waiting lists, and states planned to spend almost $2 billion directly on reducing or eliminating waiting lists.

The additional ARPA funding will end in most states by March 2025, although 4 states (Missouri, South Dakota, Virginia, and Washington) had already exhausted their funds by August 2024 and 13 states (Alaska, Georgia, Kansas, Maine, Michigan, Montana, North Dakota, New Jersey, New Mexico, Ohio, Pennsylvania, Vermont, and Wisconsin) have received extensions. Three states (California, New Mexico, and Texas), which together accounted for over half of the people on waiting lists in 2024, reported using ARPA funding to reduce or eliminate waiting lists and that continuing those reductions are a top priority. However, it is uncertain how many ARPA initiatives will be sustainable in the long run as the additional federal funds are exhausted.

A new rule on access to Medicaid services will require states to report more information about people waiting for HCBS waiver services starting in July 2027. The new rule requires states to report the number of people who are waiting to enroll in a waiver program, information on whether the people on the list have been screened for eligibility, and the average amount of time people newly enrolled in the waiver over the past 12 months had spent waiting to enroll. Although the regulation does not mention interest lists, referral lists, or registries, the preamble to the rule indicates CMS’ intent for states to report all types of lists.

Recognizing that waiting lists are an imperfect measure of unmet need, the rule also requires states to report two new measures related to access to care for people newly receiving waiver services. For people who began receiving waiver services in the past 12 months, states must also report: (1) the average length of time between approval for homemaker, home health aide, personal care, and habilitation services and the start of services and (2) the percent of authorized hours that were provided. (States may report the latter two measures for a “statistically valid” random sample of recipients.)

Despite the enhanced data states will be required to report, waiting list and waiver information will remain imperfect measures of unmet need. None of the new data will reflect how long it takes for people to receive HCBS provided through the Medicaid state plan, or how comprehensive those services are. The new data also do not capture the number of people whose authorized services are below needed levels because of hourly or dollar caps on the amount of HCBS they can receive. With most people on waiting lists still eligible for state plan services, understanding what services they receive while waiting is also a dimension in understanding how acute the needs are among people on waiting lists. More broadly, the waiting list numbers, and associated requirements, apply to waiver services only, which are optional for states to provide. New data will offer insight into unmet needs among people receiving and waiting for optional services, but there will still be little information about people who need HCBS but are not receiving care.